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ABSTRACT 
USP7 is a deubiquitinase implicated in processes such as DNA damage and tumor 
suppression. The molecular basis of interaction of USP7 with substrates is still under 
examination. One mechanism for substrate recognition is a P/AXXS motif on the 
substrate, recognized by USP7-NTD. This study involves two substrates, checkpoint with 
forkhead and ring finger domains (CHFR) and minichromosome maintenance binding 
protein (MCM-BP) involved with mitotic checkpoint and DNA replication, respectively. 
To understand the basis for interaction, co-crystal structures of USP7-NTD with 
CHFRPSTS and MCM-BPPSTS peptides were determined, which revealed a mechanism 
previously established between USP7 and p53, HDM2, HDMX and EBNA1. The 
peptides interacted within a shallow groove on the surface of USP7-NTD lined by 
residues 164DWGF167. Protein turnover assay was used to show the steady decrease of 
CHFR in the absence of USP7. This study has associated USP7 with DNA replication 
and confirmed its role at a cell cycle checkpoint.  
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CHAPTER 1: INTRODUCTION 
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Proteins are an essential part of a healthy functional cell. A vast amount of research is 
undertaken to study the pathways affected by mutations in a protein and defects in its 
regulation. Cells devote a large part of their resources to ensure appropriate synthesis and 
maintenance of these proteins, mainly through post-translational modifications. An 
important part of maintenance is the destruction or degradation of proteins, and most of 
this work is attributed to one system – the ubiquitin-proteasome system whereby a 
protein tagged with ubiquitin is targeted for proteolysis.  
1.1 Ubiquitin 
Ubiquitin is a small 8.5 kDa regulatory protein (Haglund and Dikic 2005) that gets 
conjugated to target proteins as a post translational modification. It is structurally and 
functionally highly conserved in mammals and plants, and when first discovered, it was 
observed to be expressed ubiquitously in almost all living cells including bacteria and 
yeast (Goldstein et al. 1975). When it was discovered, it was seen to be able to induce the 
differentiation of T and B cells of the immune system. Based on this and its universal 
presence in living cells, it was initially termed UBIP, or ubiquitous immunopoietic 
polypeptide (Goldstein et al. 1975). However, it was later renamed ubiquitin when it was 
discovered that UBIP does not have immunopoietic function, and it is not present in 
bacterial cells (Ciechanover 2005).  
The function of ubiquitin remained unknown until the ATP-dependent proteolytic activity 
of the cell was being studied, and the conjugation of a protein of about 8.5 kDa was 
found to be essential for recognition of the target protein by a downstream protease in the 
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presence of ATP (Ciechanover 2005). Through various tests, this factor was later found 
to be ubiquitin and its importance was established when it was found to be able to 
conjugate to H2A and H2B histone proteins in a manner that was reflective of the 
proteolytic activity studied earlier (Ciechanover 2005). The ubiquitin-proteasome system 
has since been an area with intense research dedicated to understanding it better.  
There are four genes in mammals that encode for ubiquitin, and it is synthesized bound to 
precursors, not as monomeric ubiquitin. UBB and UBC encode for polyubiquitin chains, 
whereas UBA52 and RPS27A encode for ubiquitin fused to ribosomal proteins (Kimura 
and Tanaka 2010). Upon further processing, a pool of monomeric ubiquitin becomes 
available for use in the ubiquitination process. 
The ubiquitin protein is the most conserved eukaryotic protein. One of its most important 
features is two glycine residues at its C-terminal tail, which are required for conjugation 
to target proteins. The glycine in ubiquitin forms an isopeptide bond with either the -
NH2 groups of the lysine residues on target proteins, or with their amino-terminal -NH2 
group (Vijay-Kumar et al. 1987). Ubiquitin also contains seven lysine residues, which are 
important for forming polyubiquitin chains by linking the glycine of one ubiquitin to the 
lysine of another ubiquitin that is already bound to a substrate. The seven lysines are K6, 
K11, K27, K29, K33, K48 and K63; the signal provided by ubiquitination is 
characterized based on which of these lysine residues forms the ub-ub linkage.  
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1.2 Ubiquitination 
Ubiquitin is conjugated to target proteins through a cascade of reactions. It is activated by 
E1, a ubiquitin-activating enzyme through adenylation and thioesterification of its 
carboxy-terminal carboxylate (Jin et al. 2007). It is then transferred to a cysteine residue 
in the active site of E2, a ubiquitin-conjugating enzyme, through a transthiolation 
reaction, following which an E3 ligase catalyzes its final transfer to the substrate protein 
(Ye and Rape 2009). The final transfer can occur in two ways, based on which class of 
E3 ligase is being employed. E3 with a HECT domain (homologous to E6-Ap carboxyl 
terminus) (You and Pickart 2001) gets charged with the ubiquitin from E2 in order to 
ligate it to the substrate. E3 with a RING domain (Really Interesting New Gene) 
(Deshaies and Joazeiro 2009) on the other hand, functions to bring the E2~ub complex in 
close proximity to the substrate in order to facilitate ligation (Ye and Rape 2009). The 
substrate protein is commonly ubiquitinated on the amino group of their internal lysine 
residues (Ciechanover and Saadon 2004).  
 
 
 
Figure 1.1: Ubiquitination pathway. E1 binds and activates  ubiquitin (Ub). Ub is then transferred to 
E2, following which E3 ligase catalyzes transfer of Ub from E2~Ub to the substrate. E3 with a HECT 
domain charges itself with Ub prior to ligation onto substrate. E3 with RING domain facilitates transfer 
by bringing together E2~Ub and substrate. 
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A protein tagged with ubiquitin can have proteolytic or one of many non-proteolytic fates 
in the cell, depending on whether it is mono- or poly-ubiquitinated and the type of 
linkage within the chain (Hochstrasser 2009). Polyubiquitin chains are linked via one of 
seven lysine residues on ubiquitin. A chain with K48 linkage is targeted by the 
proteasome. Monoubiquitination and polyubiquitin linkages involving any of the other 
lysines allows the protein to be recognized by ubiquitin binding domains on target 
proteins to facilitate downstream cellular processes (Hochstrasser 2009). Ubiquitination 
has implications in various processes such as cell growth, DNA repair, immune function, 
regulation of the cell cycle, membrane trafficking and histone modification (Nath and 
Shadan 2009). 
1.3 Deubiquitination 
Ubiquitination is a reversible process, whereby one or more ubiquitin molecules get 
cleaved either from the substrate or as part of modification of a polyubiquitin chain. 
Deubiquitination is catalyzed by proteases called deubiquitinases or DUBs. An essential 
part of ubiquitination is the availability of monomeric ubiquitin molecules in the cell. 
However, ubiquitin can be translated as a chain of molecules instead of monomers, or 
have ribosomal proteins fused to it (Komander et al. 2009). DUBs play a role in 
processing these precursors to provide the cell with monomeric ubiquitin molecules 
(Komander et al. 2009). DUBs are also involved in cleaving mono- or poly-ubiquitin 
chains from substrate proteins to alter their fate. For a proteolytic signal, this would mean 
rescuing the substrate from degradation. However, for a non-proteolytic signal it would 
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either remove the signal (complete cleavage) or would alter the signal by editing the 
length of the ubiquitin chain (Komander et al. 2009). 
The ubiquitinated state of a protein could differentiate between its inactive and active 
state and is involved in modulating protein-protein interactions. Malfunctioning DUBs 
have been linked to numerous diseases, including deficiencies in the immune system; 
mutations in DUBs have also been associated with cancer, thus making their normal 
functionality in the regulation of ubiquitin-dependent pathways essential for our healthy 
survival. 
  
 
Figure 1.2. Functions of DUBs in the ubiquitin pathway. DUBs modify ubiquitin precursors to provide 
the cell with monomeric ubiquitin (1). By removing the ubiquitin signal or modifying the chain, DUBs can 
reverse or edit the ubiquitin-mediated fate of the substrate proteins (2). DUBs can also recycle ubiquitin 
from conjugates with proteins targeted for degradation (3). Finally, they also recycle unanchored ubiquitin 
chains by cleaving their linkage to produce monomeric ubiquitin molecules (4). (Amerik and Hochstrasser 
2004) 
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1.4 Ubiquitin specific protease 7 (USP7) 
In humans, DUBs can be classified into two classes – cysteine proteases and 
metalloproteases – based on the catalytic domain of the protein. The cysteine protease 
class includes four superfamilies, the ubiquitin specific proteases (USP), the ovarian 
tumours (OTU), the Machado-Josephin domains (MJD) and the ubiquitin C-terminal 
hydrolases (UCH). The metalloprotease class only consists of a zinc binding 
Jab1/Mov34/Mpr1 Pad1 N-terminal+ (MPN+) (JAMM) domain superfamily (Amerik 
and Hochstrasser 2004). The focus of this project is a DUB, from the cysteine protease 
class and ubiquitin specific protease superfamily, USP7.  
1.4.1 Functional domains 
Ubiquitin specific protease 7 (USP7) contains a classic cysteine protease catalytic 
domain, whose catalytic activity involves a nucleophilic attack to break the isopeptide 
bond between the C-terminal of ubiquitin and the lysine of the substrate protein, or 
between the C-terminal of ubiquitin and the lysine of the previous ubiquitin in a 
polyubiquitin chain (Chapman et al. 1997). 
The catalytic domain of USP7 is flanked by accessory domains, with a TRAF homology 
domain on the N-terminus and five ubiquitin-like or UBL domains on the C-terminus. 
UBLs are structurally similar to ubiquitin but lack the terminal glycine residue required 
for conjugation to the lysine of the target protein (Faesen et al. 2012). The five UBLs 
together form the C-terminal domain of the protein. The N- terminal TRAF domain of 
USP7 has been found to be involved in substrate recognition and protein interaction, 
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whereas conformational changes in the UBLs in USP7-CTD have been shown to allow 
for ubiquitin binding and to enhance USP7’s catalytic activity (Faesen et al. 2012). 
 
 
 
 
1.4.2 Interactions and cellular roles 
USP7 is involved in various cellular processes including immune response, viral 
infections, DNA damage response, epigenetics and tumor suppression. Its function in 
these pathways is complimented by a vast number of substrates and interacting partners.  
It is most popularly known for its role in the p53-MDM2-MDMX pathway. p53 is a 
tumor suppressor, with essential roles in cellular and genomic stability (Li et al. 2002) 
and binds to the N-terminal domain of USP7. Under normal conditions, cellular levels of 
p53 are regulated through monoubiquitination by MDM2 which is an E3 ligase (Moll and 
Petrenko 2003). However upon oncogenic stress, USP7 through its deubiquitinating 
activity rescues p53 from degradation, demonstrating a tumor suppressor function 
(Epping et al. 2011). MDM2 is also a known binding partner of USP7-NTD, and 
NTD Catalytic CTD 
54 205 540 1 1102 
UBL 2 UBL 1 UBL 3 UBL 4 UBL 5 
564-664 684-770 793-880 894-974 986-1080 
Figure 1.3. Schematic diagram of the domains of USP7. USP7 is a 128 kDa protein containing 1102 
amino acid residues. Its N-terminal domain (NTD) consists of a TRAF-domain, from amino acid residues 
54-205. The catalytic domain is a classic cysteine protease domain from residues 208-540. The longest 
domain of the protein is its C-terminal domain (CTD), from residues 564-1080. The CTD is formed from 
five UBLs (ubiquitin-like domains), each of which is structurally homologous to ubiquitin but lacks the 
terminal glycine required for linkage.  
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interestingly, USP7 stabilizes MDM2 in addition to p53. This creates a feedback loop, 
which is a part of a regulatory mechanism to keep p53 at the required level.  
Instead of suppressing USP7, guanine monophosphate synthase (GMPS) binds to USP7 
to enhance its activity. It is a biosynthetic enzyme involved in the amidation of 
xanthosine-5’-monophosphate (XMP) to produce guanine monophosphate (GMP) 
(Nakamura and Lou 1995). It has been shown that defects in nucleotide metabolism result 
in immunodeficiency. GMPS is thus regarded as having potential for immunosuppressive 
therapy (Nakamura and Lou 1995). In 2004, research undertaken by van der Knaap and 
his colleagues revealed a role of GMPS in chromatin control. They discovered that it in 
order for histone H2B to be deubiquitinated by USP7, an association of GMPS with 
Drosophila USP7 is required, thus contributing to epigenetic silencing of homeotic 
genes. They also found this association to enhance USP7 deubiquitination of p53 (van der 
Knaap et al. 2004). 
1.4.3 Exploitation of USP7 for viral propagation 
Research has shown that a gene in breast cancer, TSPYL5, interacts with USP7 in order 
to block USP7 mediated upregulation of p53 (Epping et al. 2011). EBNA1, a protein 
from Epstein-Barr virus (EBV) is also involved in a similar mechanism to compete with 
p53 for binding to USP7, leading to downregulation of p53 mediated genes (Sheng et al. 
2006).  
Another viral protein, ICP0 is a protein from herpes simplex virus (HSV) and was the 
first protein found to bind with USP7 (Sheng et al.2006). While EBNA1 binds to the N-
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terminus, ICP0 interacts with the C-terminal domain of USP7. It also functions in a 
manner opposite to EBNA1; whereas the latter binds to USP7 to prevent it from 
performing its deubiquitinase activity, ICP0 binds to USP7 to export it to the cytoplasm 
for it to perform its role in modulating the TLR-mediated innate immune response.  
TLR or Toll-like receptors normally initiate an inflammatory response to invading 
pathogens as a part of the innate immune response. Through a cascade of reactions, the 
action of TLRs results in the activation of NF-B which is a transcription factor involved 
in the production of proteins needed for the inflammatory response (van Lint et al. 2010), 
as well as mitogen-activated protein kinases JNK and p38.  
Since this response is potent, the cell has various checks in place to avoid its hyper 
activation. One of the checks is USP7, which is responsible for regulating the TLR 
signalling using a negative feedback loop. Upon activation of the signalling pathway, 
USP7 exports to the cytoplasm and deubiquitinates K63-linked polyubiquitin chains on 
TRAF6 and IKK, which lead to inactivation of NF-B/JNK and terminate the TLR-
mediated response (Daubeuf et al. 2008). ICP0 exploits this negative feedback loop to 
inhibit the innate immune response and promote the survival and propagation of HSV.  
Besides these proteins, USP7 partners up with a vast number of proteins in the cell for 
regulation and maintenance of normal cellular functions. The fact that numerous viruses 
and cancer cells have evolved to exploit the activity of USP7 as a part of their survival 
mechanism demonstrates the importance of its function as a tumor suppressor and cell 
regulator.  
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Numerous interaction studies of USP7 with its binding partners and substrates have shed 
light on the mechanisms of its interactions. However, the molecular basis of interaction 
of USP7 with its substrates is not yet fully understood. Using X-ray crystallography, this 
project focuses on structural studies of USP7 with two of its substrates/binding partners – 
CHFR and MCM-BP - to understand these interactions at a molecular level. Additionally, 
in vivo studies assist in determining the relation between USP7 and CHFR in normal 
cellular conditions.  
1.5 X-ray crystallography 
X-ray crystallography is one of the methods used for determining protein structures. The 
method makes use of a protein crystal to diffract X-rays which produces a unique 
diffraction pattern. This pattern can be used to define the angles and intensities of the 
diffracted beams. These correspond to information about the electron density of the 
molecules which provide details on the average position of atoms in the crystal and 
chemical bonds. Refined models of atomic arrangement thus give rise to the protein’s 
three dimensional structure (Smyth and Martin 2000).  
Furthermore, co-crystal structures of a protein bound to its substrate (s) are used for 
various purposes such as drug design, to study specificity of ligands and the protein’s 
enzymatic mechanisms, for site specific mutagenesis, or in general as a finer focus to 
further previously established research (Smyth and Martin 2000). 
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1.5.1 Interaction with USP7-NTD via substrate recognition motif  
Crystal structures of the N-terminal (Saridakis et al. 2005), C-terminal (Faesen et al. 
2011) and catalytic (Hu et al. 2002) domains of USP7 have been solved individually. Co-
crystal structures of the NTD with peptides of some of its target proteins such as p53, 
HDM2, HDMX, UbE2E1 (Sarkari et al. 2010) and EBNA1 have also been established. 
Based on these structures as well as interaction assays, it is presently known that one 
mechanism for USP7 substrate recognition is by the presence of a P/AXXS motif on the 
substrate, which is recognized by a site on the N-terminal domain of USP7.  
 
 
 
 
 
 
 
 
 
Figure 1.4. X-ray crystal structures of N-terminal (top left), catalytic domain (top right) and C-
terminal (bottom) of USP7 have been determined by (Saridakis et al. 2005), (Hu et al. 2002), (Faesen et 
al. 2011), respectively. 
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1.6 Focus of this project 
Proteomics studies have revealed that USP7 interacts with two proteins - 
minichromosome maintenance complex binding protein (MCM-BP) (Sowa et al. 2009) 
and checkpoint with forkhead and ring finger domain (CHFR) (Oh et al. 2007). These 
proteins contain the P/AXXS substrate recognition motif and it is hypothesized that these 
proteins will interact with USP7-NTD and the mechanism will be similar to what has 
been previously observed in interactions with USP7-NTD involving the recognition 
motif. This project thus aims to further investigate the involvement of this motif in order 
to understand the molecular mechanism underlying these interactions. 
1.7 Preliminary work  
The objectives of this project included determining the site of interaction between USP7, 
and CHFR and MCM-BP. Both the proteins consist of multiple P/AXXS sites, and 
through preliminary work (La Delfa, unpublished) it was determined that 177PSTS180 and 
155PSTS158 from CHFR and MCM-BP, respectively, were responsible for interaction with 
USP7. Following this, mutational studies were used to confirm these sequences (La 
Delfa, unpublished). 
Using peptide array studies with USP7-NTD and peptides from CHFR and MCM-BP 
containing the PSTS motif, it was discovered that the two proteins interact with USP7-
NTD via the established substrate recognition motif, PSTS. The left panel in figure 1.5 
shows the peptide array for CHFR wild type and mutant peptides. In a peptide array, the 
appearance of a spot indicates positive interaction (La Delfa, unpublished) 
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A spot appeared for the wild type peptide 174EPQPSTSTSD183 but the interaction was 
abolished when the serines within PSTS were mutated to alanines (S178A and S180A). 
However, when a serine outside the motif was mutated, interaction was reinstated and a 
spot appeared for the S182A mutation. Similarly, the wild type MCM-BP peptide 
152RVSPSTSYTP161 displayed interaction, while the mutants did not. An EBNA1 peptide, 
which was previously shown to interact with USP-NTD, and Poly-His were used as 
positive controls (La Delfa, unpublished).  
  WT: E-P-Q-P-S-T-S-T-S-D 
 S178A: E-P-Q-P-A-T-S-T-S-D 
 S180A: E-P-Q-P-S-T-A-T-S-D 
 S182A: E-P-Q-P-S-T-S-T-A-D 
 S178A, S180A, S182A: E-P-Q-P-A-T-A-T-A-D 
CHFR 
WT: R-V-S-P-S-T-S-Y-T-P 
S156A: R-V-S-P-S-T-A-Y-T-P 
S156A, S158A: R-V-A-P-A-T-A-Y-T-P 
MCM-BP 
H-H-H-H-H-H-H-H-H-H 
D-P-G-E-G-P-S-T-G-P (EBNA1) 
H-H-H-H-H-H-H-H-H-H 
Positive control 
Figure 1.5: PSTS motif in CHFR and MCM-BP involved in interaction with USP7-NTD. A. P/AXXS 
substrate recognition sites in CHFR and MCM-BP were identified to be PSTS using peptide spot arrays. 
10-mer peptides containing the motif were used for the arrays (
174
EPQPSTSTSD
183
 and 
152
RVSPSTSYTP
161
, respectively). Interaction was observed for wild type peptides, as can be seen by the 
first spot on the arrays for CHFR and MCM-BP. Interaction was abolished when any of the serines were 
mutated within the motif (PSTS), however mutation of serine outside the motif did not affect binding. 
Positive controls for the arrays included poly-His and a previously published EBNA1 peptide.  
(La Delfa, unpublished)  
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 Peptide 
Dissociation Constant 
(Kd µM) 
CHFR 174EPQPSTSTSD183 1.6 
MCM-BP 
152RVSPSTSYTP161 9.4 
152RVSPSTAYTP161 102 
 
 
Interaction of CHFR and MCM-BP with USP7-NTD using the PSTS motif was further 
demonstrated, as shown in figure 1.6, using an intrinsic tryptophan fluorescence assay 
using the same peptides as the peptide spot array. The smaller dissociation constants for 
the wild type peptides as compared with a mutant for MCM-BP signals the use of the 
PSTS motif for binding to USP7-NTD (La Delfa, unpublished). 
  
Figure 1.6: Intrinsic tryptophan fluorescence assay to demonstrate affinity of USP7-NTD for PSTS 
motif. The binding affinity of USP7 with CHFR and MCM-BP peptides was determined using intrinsic 
tryptophan fluorescence assay. Peptides with PSTS motif bound NTD-USP7 with high affinity. Mutation 
of serine in PSTS of MCM-BP resulted in lowered affinity, with a dissociation constant of 102 uM, 
compared with 9.4 uM for wild type PSTS. 
 (La Delfa, unpublished) 
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CHAPTER 2: INTERACTION STUDY BETWEEN USP7 
AND CHFR 
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2.1 Introduction 
Chromosomal instability and propagation of mutations are major events that can lead to 
cellular transformation. As such, it is important for the cell to be able to prevent mitotic 
errors, which is achieved through various checkpoints in the cell. Upon stress or DNA 
damage, checkpoint proteins are responsible for delaying the cell cycle progression to 
prevent a compromised genome from being propagated.  
2.1.1 CHFR – the antephase checkpoint 
One such checkpoint is CHFR, which is involved in the initial response to DNA damage 
by delaying entry into mitosis. Its N-terminal domain consists of an FHA (forkhead –
associated) domain, it has a cysteine-rich C-terminus as well as a central RING domain. 
The function of the FHA domain is still under investigation, although Fukuda and 
colleagues demonstrated that the FHA domain is essential for the anti-proliferative effect 
of CHFR (Fukuda et al. 2008) and may be involved in its interaction with phosphorylated 
proteins (Li et al. 2002). The RING finger domain however, is well studied and renders 
an E3 ubiquitin ligase activity to the protein, which is utilized in its role in DNA damage 
by delaying the cell cycle progression. The known substrates of CHFR E3 ligase activity 
are PLK1, Aurora A, Kif22, HDAC1 and PARP1 (Privette and Petty 2008).  
CHFR is a cytoplasmic protein, expressed ubiquitously in normal tissues, but is 
transported into the nucleus when it senses spindle or chromosomal damage or radiation 
induced stress (Derks et al. 2013). It functions at the antephase stage of the cell cycle, 
which is a point near late G2 when the chromosomes are beginning to condense. 
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However, if the cell is introduced to certain stressors, it is able to revert back to the 
previous stage temporarily, thus delaying entry into mitosis. If the cell goes past the 
antephase into prometaphase where chromosome condensation is completely achieved 
with the breakdown of the nuclear envelope, the cell can no longer revert to a previous 
stage and is committed to mitosis (Chin and Yeong 2010).  
 
 
 
 
 
 
Figure 2.1. CHFR is an antephase checkpoint. Prior to chromatin condensation, if the cell 
encounters a stress, various checkpoints are activated to deal with the interruption to avoid the 
propagation of corrupt genome. One such checkpoint protein is CHFR, which acts at the antephase, 
by preventing the activation of the cyclinB1-CDK1 complex and reverting the cell to the previous 
phase with uncondensed chromatin and an intact nuclear envelope, thus delaying the cell cycle. 
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2.1.2 Proteasomal E3 ligase activity of CHFR  
The cyclinB1-Cdk1 pathway 
Chromosomal condensation and nuclear envelope breakdown are achieved by the action 
of a complex of kinases, cyclinB1-Cdk1. This complex is not present in an active stage 
throughout the cell cycle; it gets activated before mitosis near the end of antephase. 
CyclinB1 is always present in the cytoplasm in an unphosphorylated state, but is 
transported into the nucleus before mitosis by phosphorylation. In addition, Cdk1 remains 
phosphorylated in an inactive state, but gets dephosphorylated by Cdc25, allowing it to 
form an active complex with cyclinB1 in the nucleus (Derks et al. 2013, Berry and Gould 
1996, Hagting et al 1999). Cdc25 is also regulated by its phosphorylation state and is 
activated to carry out its function in the cyclinB1-Cdk1 pathway by PLK1 (Polo-like 
kinase 1). Finally, PLK1 is itself phosphorylated and activated by the action of another 
kinase at the top of this pyramid, called Aurora A (Derks et al 2013).  
By activating the cyclinB1-Cdk1 pathway, Aurora A and PLK1 have established an 
essential role in the commitment of the cell to mitosis, with no possibility for return to a 
previous phase. The E3 ligase activity of CHFR is involved in the ubiquitin-mediated 
destabilization of Aurora A and PLK1 (Kwon et al. 2013). By targeting the proteins for 
degradation, CHFR is able to prevent the activation of the cyclinB1-Cdk1 pathway 
resulting in cell cycle delay, allowing for the DNA damage response to be undertaken.  
Besides directly being involved in the regulation of the cyclin-cdk1 pathway, CHFR also 
plays a role in maintaining another G1 checkpoint protein p21. p21 is a cyclin-dependent 
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kinase inhibitor that directly inhibits the activity of the cyclinB1-Cdk1 pathway, amongst 
others. p21 is transcriptionally inhibited by the activity of HDAC1 (histone deacetylase 
1), which is a substrate of CHFR. By ubiquitinating HDAC1, CHFR is able to inhibit 
HDAC1, allowing for the expression of p21 and restoring the G1checkpoint (Derks et al. 
2013, Gartel and Radhakrishnan 2005).  
The PAR-PARP1 DNA damage response 
Another aspect of the E3 ligase activity of CHFR involves its recruitment to the site of 
DNA damage. PolyADP-ribose (PAR) is covalently bound to the site of damage and 
along with PAR polymerase 1 (PARP1) is involved in recovery from the damage (Liu et 
al. 2013, Ahel et al. 2008). PARP1 is continuously recycled and activated in the process 
unless removed from the DNA. Hyper-active PARP1 can cause genomic instability and 
thus its eviction from the DNA during the repair response is central to a normal recovery 
(Liu et al. 2013). PAR is recognized by a PAR-recognition motif in the C-terminus of 
CHFR. This results in the recruitment of CHFR to the site of damage where it 
ubiquitinates PARP1 for proteasomal degradation and regulates its levels for a balanced 
DNA damage response, avoiding further genomic instability (Kashima et al. 2012). 
2.1.3 Proteasome-independent E3 ligase activity of CHFR 
 In addition to its proteasome-dependent ubiquitination, CHFR employs proteasome-
independent ubiquitination to achieve various blocks in the cell cycle progression, 
including activating a p38 kinase pathway that decondenses chromosomes, as well as 
MAD2 which is a spindle assembly checkpoint (Derks et al. 2013). 
21 
 
2.1.4 Regulation of CHFR 
Analysis of cancer cell lines for CHFR expression has revealed that most tumor cells 
either undergo promoter-methylation dependent silencing of CHFR or express a mutated 
form (Toyota et al. 2003). Although its function is well understood, its regulation in the 
cell is still under investigation. Since it has functions in so many pathways as a 
checkpoint protein, it is imperative to understand how its levels are modulated in the cell.  
Every E3 ubiquitin ligase partners up with multiple E2 ubiquitin conjugating enzymes to 
perform their ubiquitination function. There are several known E2 partners of CHFR 
including UbE2D1, UbE2D2 and UbE2D3 for its K48-linkage polyubiquitination and a 
heterodimer enzyme complex of UbE2N-MMS2 for the K63-linked polyubiquitin chains 
(Privette and Petty 2008). However, this list is not exhaustive, and there are E2 enzymes 
that haven’t been tested with CHFR yet. RNF8 is a CHFR homolog that is also involved 
in the DNA damage response, and contains FHA and RING domains similar to CHFR. 
Interestingly, the two RING domains are interchangeable and in fact use similar E2 
partners (Liu et al. 2013). One of the E2 partners of RNF8 is UbE2E1 (Ito et al. 2001), 
and since RNF8 shares a RING domain with CHFR, this could also be a potential E2 
partner of CHFR. 
Being an E3 ligase, CHFR is capable of auto-ubiquitination targeted towards keeping a 
low level of itself in normal cells, and is one of the key events involved in a normal 
mitotic entry (Kim et al. 2011). Interestingly, USP7 was found to interact with CHFR 
(Oh et al. 2007), providing a link to its method of regulation.  
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2.1.5 Objectives 
CHFR contains a P/AXXS (PSTS) motif and the purpose of this project is to determine if 
it interacts with the N-terminal domain of USP7, and to structurally determine if the 
recognition motif in CHFR is responsible for the interaction.  
Further, in vivo expression levels of CHFR in the absence of USP7 were tested using 
HEK293T cells in which CHFR is endogenously expressed, with USP7 silenced using 
siRNA. As a result, the effect of USP7 on CHFR stability can be determined, confirming 
a role for USP7 directly at a mitotic checkpoint.  
This project also aimed to determine if UbE2E1 is a ubiquitin-conjugating partner of 
CHFR using a co-immunoprecipitation assay.  
2.1.6 Techniques employed to achieve objectives 
In order to test whether CHFR interacts with the N-terminal domain of USP7, a GST 
pull-down assay was used with USP7-NTD expressed as a GST-fusion protein and cell 
lysate expressing CHFR was applied to it to pull-down CHFR. 
The method employed to test the stability of CHFR is called a protein turnover assay. 
This technique monitors the half-life a protein after blocking the translational machinery. 
The translation machinery is blocked by a chemical called cycloheximide, which is 
derived from Streptomyces griseus and inhibits the elongation stage of protein translation 
in eukaryotes (Schneider-Poetsch et al. 2010). The advantage of this technique is that the 
half-life of proteins can be visualized without the need to account for newly synthesized 
protein. 
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The interaction between CHFR and UbE2E1 was tested using a co-immunoprecipitation 
assay. In this assay, a protein of interest is isolated from a cell lysate using antibody 
specific to the protein, bound to beads to immobilize it and blotted for a second 
interacting protein that is being tested. If the two proteins interact, the interacting protein 
would have co-immunoprecipitated with the protein of interest and could be visualized in 
the same fraction. However, if the two proteins don’t interact, the interacting protein 
would be recovered in a separate unbound fraction.  
2.1.7 Hypotheses 
It is hypothesized that CHFR will interact with USP7-NTD and that the PSTS motif is 
responsible for this interaction, where the mechanism of interaction will be similar to 
what has previously been observed with interaction of USP7 and p53, Hdm2, HdmX and 
EBNA1. 
In the in vivo protein turnover assay, it is expected that in cells lacking USP7, 
endogenous CHFR will get degraded faster, or have a shorter half-life, than in the 
presence of USP7 due to the lack of deubiquitinating activity of USP7.  
In determining whether RNF8 and CHFR share the E2 ubiquitin conjugating enzyme, it is 
expected that UbE2E1 will interact with CHFR.  
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2.2 Materials and Methods 
2.2.1 PCR amplification of CHFR 
A plasmid encoding for the human CHFR cDNA was obtained from the Mammalian 
Gene Collection (Clone ID: 4650348). The cDNA was PCR amplified using forward 
primer 5’-GCA CTC GAG CTA TGG AGC GGC CCG AGG AA-3’ and reverse primer 
5-CAG GGT ACC GTT TTT GAA CCT TGT CTG TTC ACA-3’, with XhoI and KpnI 
digestion sites incorporated into the primers, respectively. Eight annealing temperatures 
were used to test for optimal product. Each reaction was performed in a final volume of 
50 µl and contained 3mM MgSO4, 0.3mM each of the dNTPs, 1XPfu Buffer (20mM 
Tris-HCl pH 8.8, 1mM MgSO4, 10mM KCl, 10mM (NH4)2SO4, 0.1% Triton X-100, 0.1 
mg/ml nuclease-free BSA), 50 pmol each of forward and reverse primers, DNA template 
and 0.05U/µl Pfu DNA polymerase. A thermocycler with a temperature gradient block 
was used to set up the PCR. Following is the PCR program used: 
Step Temperature (⁰C) Time No. of Cycles 
Initial Denature 95 10 min 1 
Denature 
Annealing 
Extension 
95 
X 
72 
1 min 
1 min 
5 min 
30 
Final Extension 72 20 min 1 
“X” under Annealing Temperature refers to a gradient of the annealing temperatures used: 56.1⁰C, 56.7⁰C, 
58.1⁰C, 59.0⁰C, 59.9⁰C, 60.9⁰C, 61.9⁰C, 63.0⁰C 
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The PCR products were separated on a 1% agarose gel for 40 mins at 100V (5 µl sample 
+ 1 µl 6xDNA dye) to test for the presence of a 1.9 kb DNA band representing the 
amplified DNA. The PCR products were then gel purified to isolate the desired DNA. 
2.2.2 Isolation of amplified CHFR DNA 
The amplified DNA was isolated by separating the products on a 1% agarose gel, 
excising the desired band and extracting the DNA using the illustra GFX PCR DNA and 
Gel Band Purification Kit (GE Healthcare). The DNA was eluted in 50 µl ddH2O.  
2.2.3 Cloning CHFR into pCMV3FC mammalian vector 
The gel extracted CHFR DNA was serially digested using XhoI (NEB) in 1XNEB1, 
1XBSA, and using 1µg DNA in a 50 µl volume at 37⁰C overnight, followed by heat 
inactivation at 65⁰C for 20 minutes and digesting with KpnI with the same conditions as 
that for XhoI in a 60 µl reaction volume at 37⁰C for 10 minutes. The digested DNA was 
subjected to a reaction cleanup using the illustra GFX PCR DNA and Gel Band 
Purification Kit (GE Healthcare) and eluted with 50 µl ddH2O. The digested DNA was 
ligated with XhoI/KpnI digested pCMV3FC mammalian vector (encoding for a C-
terminal 3XFlag) using T4 DNA Ligase (NEB), incubated overnight at 37⁰C.  
The ligated DNA was electroporated into Escherichia coli DH5 electrocompetent cells 
(1 µl DNA + 25 µl cells), plated onto LB agar plates with 50 ng/ml kanamycin for 
selection and incubated overnight at 37⁰C. Of the resulting colonies, 8 were picked and 
cultured overnight in 5 ml of LB broth with 50 ng/ml kanamycin at 37⁰C. Plasmid DNA 
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was isolated from the resulting culture using the QIAprep Spin Miniprep Kit and the 
DNA was eluted with 50 µl ddH2O. To check for the presence of the correct insert, a 
XhoI/KpnI serial double digest was set up as before and the resulting samples were 
separated on a 1% agarose gel. The positive clone was confirmed with sequencing and 
the plasmid encoded for Flag-CHFR. 
2.2.4 Testing interaction of CHFR with USP7-NTD using GST pull-down 
The interaction between CHFR and the N-terminus of USP7 (amino acid residues 54-
205) was tested using GST pull-down, with GST-tagged USP7-NTD. 
E. coli BL21 (DE3) MGK cells with a pGEX2tk plasmid encoding for GST-USP7-NTD 
were cultured in Terrific Broth (TB, Bioshop) with 100 ng/ml ampicillin and 50 ng/ml 
kanamycin and protein expression was induced using 0.4mM IPTG (Bioshop), overnight 
at 16⁰C. The cells were harvested at 7,446 x g for 30 minutes in a Beckman-Coulter 
centrifuge with rotor JLA 9.1 at 4⁰C.  0.5 g of the resulting pellet was lysed using 2 ml of 
1XPBS with 1XProtease inhibitor cocktail (0.05mM phenylmethylsulfonyl fluoride 
(PMSF), 0.1mM benzamide, cold absolute ethanol) at 30% amplitude, 20 sec ON 15 sec 
OFF for a total ON time of 80 seconds. The lysed cells were centrifuged at 21,339 x g for 
10 minutes at 4⁰C. A 50 µl sample of the lysate was stored to be used for analysis, and 
the remaining lysate was subjected to glutathione beads equilibrated with 1XPBS. The 
protein was allowed to bind to the GST resin for 1 hour at 4⁰C with rotating. The 
resulting unbound fraction was collected and the resin was washed three times with 1 ml 
of 1XPBS. The last wash was collected and the resin was ready to be used for the GST 
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pull-down. This exact procedure was also carried out for GST protein to be used as a 
negative control. 
 HEK293T cells were cultured with DMEM media supplemented with 5% FBS and 
transfected with 10 µg of the Flag-CHFR plasmid using Lipofectamine 2000 Transfection 
Reagent (Life Technologies). The cells were harvested 48 hours post transfection by 
washing three times with 1XPBS. The resulting cell pellet was lysed using 50mM Tris 
pH 8, 150mM NaCl, 0.5% NP-40, 1XProtease inhibitor cocktail and 1XProtease inhibitor 
tablet (Roche cOmplete ULTRA Tablets). The cells were allowed to lyse for 15 minutes 
at 4⁰C with rotating followed by sonication at 10% amplitude with 1 sec ON 1 min OFF 
for a total ON time of 3 seconds. The lysed cells were centrifuged at 17,000 x g for 10 
minutes at 4⁰C. 50 µl of the resulting lysate was stored as input. The NaCl concentration 
in the remaining lysate was diluted to 50mM with 50mM Tris pH 8 to prevent 
interference during interaction. 1XPBS was also diluted 3 times to reduce the salt 
concentration. 
 Diluted Flag-CHFR lysate (250 µl ) with 300 µl of diluted PBS, 250 µl of ddH2O and 
1XProtease inhibitor cocktail were added to the GST-USP7-NTD and GST resins and 
were left rotating overnight at 4⁰C. The resulting unbound fractions were collected and 
the resin was washed three times with 500 µl of diluted PBS. A sample of the beads was 
taken at this point (beads pre-E) and the GST-tagged proteins were eluted with 20mM 
reduced glutathione (GSH) by incubating the resin with 500 µl with rotating at room 
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temperature for 15 minutes. The beads were then centrifuged and the supernatant 
collected as elution. A sample of the beads was also taken post elution (beads post-E).  
A 10% SDS gel was run with 10 µg of Flag-CHFR lysate and samples from the unbound 
fraction, beads pre-E, elution (E) and beads post-E, for both the pull-downs.  The gel was 
run at 70V for the first 30 minutes (through the stacking gel) and 195V for the next 40 
minutes. The proteins were transferred to a PVDF membrane at 100V for 75 minutes at 
4⁰C. The membrane was blocked for an hour with 5% milk in PBS at room temperature 
and blotted overnight with an anti-Flag primary antibody (Sigma F3165) at 1:1000 
dilution. The membrane was washed 3 times with 1XPBS-T for 5 minutes each, with 
rinsing with 1XPBS in between each wash. It was then blotted with an anti-mouse HRP 
secondary antibody for 1 hour at room temperature at 1:20,000 dilution, followed by 
three washes of 15 minutes each. The membrane was incubated in ECL solution (GE 
Healthcare) for 1 minute, exposed onto a film for 30 seconds and the film developed to 
visualize Flag-CHFR. The membrane was then stripped of the current antibodies by 
boiling it with 50mM Tris pH 6.8, 2% SDS, 100mM -Me and washed for 10 minutes 3 
times. The blotting was repeated at before with an anti-GST primary antibody (Novagen 
71097) at a 1:4000 dilution and an anti-mouse HRP secondary antibody at a 1:20,000 
dilution. The film was exposed for 1 minute and developed to visualize GST-USP7-NTD 
and GST proteins. 
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2.2.5 Molecular basis of interaction between USP7-NTD and CHFR 
Expression and purification of USP7-NTD 
E. coli BL21 (DE3) cells containing a plasmid encoding for 6xHis-tagged USP7-NTD 
were cultured in TB with 100 ng/ml ampicillin and expression was induced overnight 
using 0.4mM IPTG at 16⁰C. The cells were harvested at 7,446 x g for 30 minutes at 4⁰C. 
The resulting pellet was lysed with 4 ml of Lysis Buffer per gm of pellet (100mM Hepes 
pH 7.5, 500mM NaCl, 10% glycerol, 10mM Imidazole, 0.5mM TCEP, 1XProtease 
inhibitor cocktail). The cells were sonicated at 30% amplitude, 15 sec ON 10 sec OFF for 
a total ON time of 6 minutes, with a pause after 3 minutes. The lysed cells were 
centrifuged at 41,287 x g for 30 minutes at 4 ⁰C. A sample was taken from the 
supernatant for SDS PAGE analysis and the remaining lysate was incubated with Ni2+ 
agarose beads equilibrated with the Lysis Buffer, with gentle rocking at 4⁰C for 2 hours. 
The proteins left unbound after binding were collected and the resin was washed with 100 
ml of Wash Buffer (100mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 25mM 
Imidazole, 0.5mM TCEP). The wash was collected and the isolated protein was eluted 
with Elution Buffer (100mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 250mM 
Imidazole, 0.5mM TCEP).  
Samples obtained from lysate, unbound proteins, wash and elute (16 µl sample + 4 µl 
5XSDS dye) were resolved on a 10% SDS gel at 195V for 65 minutes and a PageRuler 
Prestained Protein Ladder was used as a MW reference. 
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The purified 6xHis-USP7-NTD contains a thrombin cleavage site between the His-tag 
and the protein. To cleave the 6xHis-tag, the protein was incubated with 0.5 units 
thrombin (Sigma T6884) per mg protein and 2.5mM CaCl2 for 72 hours at 4⁰C. Samples 
of the protein were taken before and after cleavage (His-uncleaved and His-cleaved, 
respectively) and resolved on a 15% SDS gel run at 220V for 35 minutes. The marker 
used was PageRuler Prestained Protein Ladder.   
The His-cleaved USP7-NTD was then subjected to size exclusion chromatography 
HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare) on an AKTA Purifier 
(GE Healthcare) to further remove impurities from the protein and to exchange the 
protein into 20mM Hepes pH 7.5, 500mM NaCl. The cleaved dialyzed protein was used 
for protein crystallization trials.  
Co-crystallization trials of USP7-NTD with CHFRPSTS peptide 
USP7-NTD was concentrated to 100 mg/ml and mixed with 5-fold molar excess of 
CHFR peptide 174EPQPSTSTSD183 with N-terminal acetylation and C-terminal amidation 
(synthesized by CanPeptide Inc.) and incubated overnight at 4⁰C. Co-crystal trials were 
set up using micro-seeding with USP7-NTD:HdmX as seeds in 0.1 M Tris pH 8.5, 30% 
PEG 4000, and 0.2 M Lithium Sulfate.  
X-ray data collection and molecular structure determination 
A USP7:CHFR crystal was frozen and X-ray diffraction data was collected at 100K on a 
Rigaku MicroMax007 rotating anode diffractometer with a 944+ CCD (charge-coupled-
device) detector. HKL2000 was used to integrate and scale the diffraction data and 
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molecular replacement was used to determine the structure (Otwinowski and Minor 
1997). USP7 54-205 (PDB identifier [ID] 1YY6) without any peptide was used as the 
search model in CNS program (version 1.3) (Brunger 2007). The electron density was 
visualized and the model was rebuilt using the molecular graphics program O (Jones and 
Kjeldgaard 1997). CNS 1.3 was used for refinement and 2Fo-Fc and Fo-Fc maps were 
inspected for further refinement and model rebuilding in O. Water molecules were picked 
using CNS 1.3 and verified in O. The figures were created using the software program 
PyMOL (version 1.3). 
2.2.6 Determining cellular effect of USP7 on CHFR 
Comparing the stability or turnover of CHFR in the presence and absence of USP7 
For the turnover assay, cells were harvested at six time points (0, 2, 4, 8, 24, 48 hour); 
thus the experiment was carried out in 6-well plates with a 2 ml working volume per 
well. Two sets of 6-well plates were used - one for experimental (siUSP7) and one for 
negative control (siNC).  
HEK293T cells were transfected separately with siRNA for USP7 (siUSP7) and negative 
control (siNC) using 30nM siRNA and LipoJet In Vitro Transfection Kit (SignaGen 
Laoratories). The cells were incubated for 72 hours post transfection to allow for 
sufficient silencing of USP7. The cells were then split into 6-well plates, allowed to settle 
for 3 hours and subjected to 50 µg/ml cycloheximide treatment. The cells were harvested 
at 0, 2, 4, 8, 24 and 48 hour time points post cycloheximide treatment, washed three times 
with 1XPBS. 
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The resulting cell pellet was lysed with 50mM Tris pH 8, 150mM NaCl, 0.5% NP-40, 
1XProtease inhibitor cocktail and 1XProtease inhibitor tablet (Roche cOmplete ULTRA 
Tablets) for 15 minutes at 4⁰C with rotating, followed by sonication at 10% amplitude 
with 1 sec ON and 1 min OFF for a total ON time of 3 seconds. The lysed cells were 
centrifuged at 17,000 x g for 10 minutes at 4⁰C. 10 µg of the lysates were subjected to 
SDS PAGE on 10% SDS gels (four gels) at 195V for 65 minutes. The proteins were then 
transferred to PVDF membranes and subjected to Western Blotting at 100V for 1 hour.  
The membranes were cut to allow for separate blotting of CHFR and GAPDH which was 
used as a loading control. They were blocked for 1 hour with 5% milk in 1XPBS and 
blotted with anti-CHFR (Abcam, 1:100 dilution) and anti-GAPDH primary antibodies for 
1 hour and washed with 1XPBS-T three times for 5 minutes each with rinses with 1XPBS 
between each wash. They were then blotted with anti-mouse HRP secondary antibody for 
45 minutes and washed with 1XPBS-T three times for 15 minutes each. The membranes 
were incubated with ECL solution for 1 minute and a film was exposed to the 
membranes. The membranes were then stripped and re-probed with anti-USP7 primary 
antibody (Bethyl, 1:10,000 dilution) and anti-rabbit HRP secondary antibody.  
2.2.7 Testing if UbE2E1 and CHFR are interacting partners  
Co-immunoprecipitation (Co-IP) with endogenous UbE2E1 and over-expressed CHFR 
10 µg Flag-CHFR was transfected in HEK293T cells and harvested 48 hours post 
transfection and lysed with 50mM Tris pH 8, 150mM NaCl, 0.5% NP-40, 1XProtease 
inhibitor cocktail and 1XProtease inhibitor tablet (Roche cOmplete ULTRA Tablets), as 
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described previously. The proteins were immunoprecipitated with Flag and blotted for 
Flag and UbE2E1. To accomplish this, 1 mg of lysate was incubated with 2 µg of rabbit 
anti-ECS (DDDK or Flag) antibody and 2 µg of anti-IgG antibody (negative control), 
separately, and left rotating at 4⁰C overnight. This was applied to 15 µl of Protein A/G 
Plus-Agarose beads pre-cleared with 5% BSA in 1XPBS and incubated for 1 hour with 
rotating at 4⁰C to immobilize the immunoprecipitated protein (Flag-CHFR and IgG) and 
any protein bound to it. After incubation the unbound protein fraction was collected by 
centrifuging the samples at 8,000x g for 1 minute and collecting the supernatant. The 
beads were then washed four times with 0.5 ml of 50mM Tris pH 8, 150mM NaCl, 0.5% 
NP-40, 1XProtease inhibitor cocktail and 1XProtease inhibitor tablet (Roche cOmplete 
ULTRA Tablets) and the last wash was collected. 30 µl of 5XSDS dye was added to the 
samples, boiled for 3 minutes, centrifuged at 8,000 x g for 1 minute and the supernatant 
was collected as the eluate.  
Two 10% SDS gels were run with the same samples (from IP: Flag and IP: IgG) and 
subjected to Western blotting to visualize Flag-CHFR and UbE2E1 separately. The gel 
that was blotted for Flag-CHFR had 10 µg of the lysate (input), 10 µl each of the 
unbound and wash samples and 5 µl of the eluate. The gel that was blotted for 
endogenous UbE2E1 contained 30 µg of input, 20 µl each of the unbound and wash and 
25 µl of the eluate. The gels were run at 195V for 65 minutes, the transfer was set up at 
100V for 1 hour and the membranes were blotted with mouse anti-Flag and anti-UbE2E1 
primary antibodies and anti-mouse HRP secondary antibodies.    
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2.3 Results 
2.3.1 E3 ligase CHFR interacts with the N-terminal domain of USP7 
CHFR cDNA was amplified using PCR (Figure 2.1A), digested with XhoI and Kpn1, 
cloned into pCMV3FC mammalian expression vector and the ligated product was 
electroporated into E. coli DH5 cells. Plasmids were isolated from the resulting colonies 
and digested with Xho1 and Kpn1 to test for the presence of the correct 1.9 kb CHFR 
insert. As seen in figure 2.1B, of the eight colonies tested, one yielded a positive insert at 
1.9 kb along with the plasmid backbone.  
GST pull-down using GST-USP7-NTD and Flag-CHFR 
To determine if the interaction of CHFR is with the N-terminal domain of USP7 (USP7-
NTD), a GST pull-down of Flag-CHFR (lysate from HEK293T cells expressing Flag-
CHFR) with GST-USP7-NTD was performed. A pull-down of Flag-CHFR with GST was 
also performed to serve as a negative control. Figure 2.2 displays a western blot of the 
samples taken from the pull-downs. Lanes 3 and 5 contain samples of beads taken pre-
elution and post-elution, respectively, and these contain any protein that was bound to the 
beads. The membrane was blotted with anti-Flag and anti-GST to visualize Flag-CHFR 
and GST-tagged proteins, respectively. Even though a small fraction of Flag-CHFR is 
seen in the unbound fraction in the pull-down with USP7-NTD, Flag-CHFR is evident in 
lanes 3 and 5, as well as a faint band present in the eluate in lane 4; GST-USP7-NTD is 
also present in the same samples. However, in the pull-down with GST, Flag-CHFR is 
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not present in the samples with GST (lanes 7 and 8), only in the unbound fraction, 
suggesting that CHFR bound to GST-USP7-NTD.  
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Figure 2.2: PCR amplification and cloning of CHFR into mammalian expression 
vector pCMV3FC. A) CHFR cDNA was PCR amplified at eight annealing 
temperatures to test for optimal product. It could be amplified at all the temperatures 
except 61.9⁰C. XhoI and KpnI digestion sites were incorporated into the primers. The 
PCR products were gel purified to isolate the desired DNA at 1.9 kb, digested with 
XhoI and KpnI and ligated with cut pCMV3FC vector. The resulting plasmid was 
cloned into E. coli DH5 cells. B) Plasmids were obtained from resulting colonies and 
digested with XhoI/KpnI to test for positive insert. Seven of the tested colonies were 
false positives, whereas one showed an insert at 1.9 kb, highlighted in green in the 
figure. The positive clone was confirmed with sequencing. The samples were separated 
on a 1% agarose gel, run at 100 V. The ladder used was GeneDireX 1 kb RTU DNA 
Ladder.  
1.9 kb  
CHFR 
XhoI/KpnI digests of cloned plasmid DNA isolated from 
colonies B 
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Figure 2.3: GST pull-down shows interaction between CHFR and USP7-NTD. Cell 
lysate from HEK293T cells overexpressing Flag-CHFR was subjected to glutathione 
beads bound to GST-USP7-NTD and interaction was allowed to happen overnight. GST 
was used in place of GST-USP7-NTD as a negative control. The unbound fractions 
containing proteins that did not interact with USP7-NTD or GST were collected (lanes 2, 
6). The beads were washed with PBS and eluted with 20 mM GSH (lanes 4, 7). Beads 
pre-E (lane 3) and post-E (lanes 5, 8) refer to a sample of beads taken before and after 
elution, respectively. A 10 ug lysate sample from 293T cells was used as input (lane 1). 
The samples were resolved by SDS-PAGE and transferred to a PVDF membrane for 
Western Blotting. Ant-flag antibody was used to detect Flag-CHFR (top panel), the 
membrane was stripped and anti-GST antibody was used to detect GST-USP7-NTD and 
GST (bottom panel). Flag-CHFR can be seen present on the beads with GST-USP7-NTD 
in lanes 3 and 5 along with a small amount seen in elution in lane 4. Note: low amount of 
flag-CHFR in elution was due to insufficient elution, as can be seen from GST-USP7-
NTD left on the beads after elution as well. However, when compared with GST and the 
absence of flag-CHFR in elution (lane 7) and beads post-E (lane 8), it is evident that 
CHFR interacts with USP7-NTD. 
293T  
10 ug 
Pull-down with 
 GST-USP7-NTD 
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Pull-down with 
 GST  
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2.3.2 Molecular basis of interaction of USP7 with CHFRPSTS involves its 164DWGF167 
binding pocket 
Purification of His-USP7-NTD 
To determine the molecular basis of interaction, co-crystal structure of USP7-NTD with a 
peptide from CHFR (174EPQPSTSTSD183) was determined using X-ray crystallography. 
USP7-NTD was purified using Ni2+ affinity chromatography (Figure 2.3A) and exposed 
to thrombin to cleave the 6xHis tag (Figure 2.3B). The small difference in sizes of 
uncleaved and cleaved proteins in figure 2.3B (18.5 kDa and 17.8 kDa, respectively), 
show successful removal of the 6xHis tag from the protein. 
Co-crystallization trials and molecular structure determination  
The cleaved USP7-NTD was successfully co-crystalized with 5-fold excess of CHFR 
peptide in 0.1M Tris pH 8.5, 30% PEG 4000 and 0.2M Lithium Sulfate using micro-
seeding with crystals from the USP7-NTD:HdmX complex as seeds to produce long, rod-
shaped crystals as seen in figure 2.4. These crystals were used to diffract X-rays and the 
diffraction patterns were used to determine the three-dimensional structure of the 
complex. Figure 2.6 displays one of the diffraction images collected for a complete data 
set. The first image (figure 2.6A) is lighter to show the reflections in the medium 
resolution shells. Spots can clearly be seen until the 2.44Å shell. However, reflections at 
higher resolutions can be viewed in figure 2.6B, with a magnified region around 2.1Å. 
Each spot on the image is a reflection created by the constructive interference of X-rays 
when they get diffracted through a crystal.  
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Using molecular replacement, the USP7-NTD:CHFRPSTS structure was solved to 1.6Å. 
Table 2.1 lists the X-ray data collection and refinement parameters for the structure. The 
space group was P41 with a = b = 70.0 Å and c = 45.7 Å unit cell parameters. At the 
highest resolution shells the data was found to be 50%. The Ramachandran plot values 
with 97.3% of the residues at their favored regions signals the validity of the determined 
structure.  
CHFR binds to the -7 strand of USP7 
Figure 2.7A displays the molecular structure, with USP7-NTD depicted as a ribbon 
diagram in chocolate brown and the peptide represented in yellow (CHFR) in stick-form. 
The N-terminal domain of USP7 consists of an anti-parallel beta-sandwich of eight -
strands that resembles a TRAF domain. This domain was modelled from residues 63-205 
instead of 54-205 since the initial residues were too disordered to assign an atomic 
structure. The CHFR peptide interacts with the 7 strand of USP7-NTD and is situated 
such that it hugs the two beta-sheets along its length. The orientation of the structure, as 
visualized in figure 2.7A, will be referred to as the frontal view since it provides the 
optimal view of the peptide and protein together. Figures 2.7B and C represent surface 
and electrostatic charge diagrams of the structure, respectively, both in frontal view.  
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Figure 2.4: Purification of USP7-NTD using Ni2+ affinity chromatography. A) 
6xHis tagged N-terminal domain of USP7 (residues 54-205) was overexpressed in E. 
coli cells and purified using Ni2+ affinity chromatography. Samples from lysate, 
unbound proteins, wash and elute were collected and separated on a 15% gel at 195V 
for 65 minutes A band can be seen in Elute at ~18.5 kDa, representing 6xHis-USP7-
NTD. B) The purified protein was incubated with thrombin for ~72 hrs at 4⁰C to cleave 
the 6xHis tag. The difference in MW of uncleaved and cleaved protein can be seen at 
18.5 kDa and 17.8 kDa, respectively. The cleaved protein was subjected to size 
exclusion chromatography for use in X-ray crystallography. Samples were separated 
on a 15% gel at 220V for 35 minutes. The ladder used for both the gels was PageRuler 
Prestained Protein Ladder.   
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Figure 2.5: Protein crystals of USP7-NTD complexes with CHFR peptide. 100 mg/ml 
USP7-NTD was incubated with approximately 5-fold excess of CHFR
PSTS
 peptide. Co-
crystal trials were set up using micro-seeding with USP7-NTD:HdmX as seeds in 30% 
PEG 4000, 0.1 M Tris pH 8.5 and 0.2 M Lithium Sulfate. Crystals were obtained in the 
dark at 4⁰C and used to collect X-ray data and solve the three-dimensional structures of 
the USP7-NTD:CHFR
PSTS
 complex. Shown here are the long rod-shaped crystals obtained 
from complex of USP7-NTD with CHFR peptide 
174
EPQPSTSTSD
183
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Figure 2.6: X-ray diffraction pattern from a USP7:CHFR complex crystal. X-ray data 
from a Rigaku MicroMax007 rotating anode diffractometer with a 944+ CCD (charge-
coupled-device) detector was collected at 100K from a frozen protein crystal. When the 
X-rays pass through the crystal, a constructive interference of the X-rays produce 
reflections on the detector, which as seen as spot on the images. A. Image of the diffraction 
pattern displaying reflections at the low-medium resolution shells. B. Image showing the 
reflections at the higher resolution shells, with a magnified section around 2.11Å.  
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Table 2.1. X-Ray data collection and refinement parameters for 
USP7:CHFR complex structure 
Numbers in brackets refer to the highest resolution shell, 1.60 Å for the CHFR
PSTS
 data. 
a
R
sym
 = S |I-
<I>| /SI where I is the observed intensity and <I> is the average intensity from multiple observations 
of symmetry-related reflections.  
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Figure 2.7: Crystal structure of USP7-NTD bound to CHFR 
174
EPQPSTSTSD
183
. A. 
The CHFR peptide in yellow stick form is seen bound to the -7 strand of USP7, which is 
represented in a chocolate ribbon diagram. B. Surface diagram and C. Electrostatic surface 
representation of the crystal structure. The complex structure was solved at a resolution of 
1.6 Å.  
A 
B 
C 
-7 
C 
N 
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By binding to the -7 strand, CHFR sits in a shallow groove on the surface of USP7 
To view the structure from a different angle, it was rotated 90⁰ on its x-axis from the 
frontal view, as seen in figure 2.8. Figure 2.8A displays this in ribbon diagram, whereas 
2.8B represents USP7 in surface diagram. In the surface diagram, upon rotation, a groove 
on the surface of USP7 is evident in which CHFR fits. The corresponding ribbon diagram 
shows that the -7 strand of USP7 is a part of the base of this groove. 
The interaction site – S180 of CHFR makes most contacts with D164 of USP7 
The CHFR peptide was aligned with USP7 and a detailed look was taken at the 
interaction site. From figure 2.9A, it is evident that the tight binding between CHFR and 
USP7 is owed to two interactions. Figure 2.9B and C are rotated views of 2.9A to provide 
clarity and highlight each individual interaction. The most important bonding that takes 
place is between S180 (Ser180) of CHFR and D164 (Asp 164) of USP7. The carboxyl 
groups of the side chain of D164 form direct hydrogen bonds with the hydroxyl of the 
serine side chain of S180 as well as the amide of S180 (figure 2.9B). The other 
interaction that aids in binding are water-mediated hydrogen bonds between S178 of 
CHFR with USP7 (figure 2.9C). The groove on the surface of USP7 is lined by residues 
164DWGF167, and it is these interactions that allow the peptide to bind in the groove.  
To provide orientation clarity, the orientation of the peptide observed in figure 2.9B is 
considered as the standard orientation, and will be used with every depiction of the 
peptide, along with a rotated view to provide the optimal visualization of the site of 
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interest. Figure 2.9A is an electron density map of the peptide, also in the standard 
orientation.  
CHFR peptide forms a beta-strand anti-parallel to -7 of USP7 
In order to see if there is any secondary structure relation between USP7 and the CHFR 
peptide, CHFR was displayed as a strand and compared with its stick-form. This is shown 
in the frontal view of the complex structure, as well as a rotated view in three dimensions 
to better observe their alignment. Figure 2.10A shows these two orientations with CHFR 
in stick form. In the rotated view, the peptide is seen to lie adjacent to the -7 strand of 
USP7. Interestingly, with the peptide in ribbon diagram, in figure 2.10B, it forms an anti-
parallel strand to USP7.  
Comparing the substrate recognition motif of CHFR with USP7 interacting peptides 
Figures 2.11-2.13 compare the CHFR peptide with other USP7-NTD interacting peptides 
from MDM2, p53 and EBNA1, respectively, by aligning these peptides with CHFR. The 
PSTS motif of CHFR is compared with the respective motifs of the other proteins. 
MDM2 uses a PSSS motif, which differs only by one residue from the PSTS motif of 
CHFR, and the motifs can thus be seen to align well. The PGGS of p53 only shares the 
proline and last serine with CHFR, but still maintains the P/AXXS conservation. EBNA1, 
however, uses EGPS, which deviates from the P/AXXS used by CHFR as well as the 
other proteins. This peptide in general does not align with CHFR, except for the last 
serine in the motif which interacts with D164 of USP7, which is conserved and aligns 
perfectly.  
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Figure 2.8: CHFR binds to a shallow groove on the surface of USP7. The figures on 
the left in A and B depict the frontal view of the structures, with a clear view of both the 
USP7-NTD structure as well the peptide bound to it. Upon rotating the structure on the 
x-axis at a 90⁰ angle, the CHFR peptide is observed to be sitting in a shallow groove on 
the surface of USP7. At the base of the groove is the -7 strand of the anti-parallel beta-
sheets of the N-terminal domain of USP7. A. Cartoon and B. Surface representations of 
the frontal view as well as the rotated, to allow for visualization of the binding groove. 
The peptide is represented in yellow stick form.  
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Figure 2.9: CHFR 177PSTS180 interacts with 164DWGF167 in the binding groove of 
USP7. A. The electron density map (2fo-fc) of the CHFR peptide. B. The peptide in 
yellow aligned with the interacting residues of USP7, in chocolate. C. Direct hydrogen 
bonds are made between the peptide and protein using S180 (Ser180) of CHFR and D164 
(Asp164) of USP7. D. Additional interaction is established by water-mediated hydrogen 
bonding using S178 of CHFR with USP7. C. and D. are rotated views of A, to better 
display the S158-D164 and the water-mediated interactions, respectively.  
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Figure 2.10: The CHFR peptide forms an antiparallel strand. A. When the 
USP7:CHFR structure is rotated from its frontal view in three dimensions, the peptide, 
in stick form, is seen to line up against the upper beta-sheet of USP7. Viewing the 
peptide as a strand instead of stick-model, as seen in B, enables visualization of it as 
forming an anti-parallel strand to the -7 strand of USP7.  
A B 
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Figure 2.11: The USP7 binding motif of CHFR 177PSTS180 compared with that of 
MDM2 147PSSS150. A. An orientation of the CHFR peptide used to provide a standard 
view amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. The PSTS motif of CHFR is aligned with PSSS of 
MDM2. The difference in T179 of CHFR and S149 of MDM2 can be seen, with CHFR 
in yellow and MDM2 in red. The most important residues, CHFR S180 and MDM2 
S150 align well. 
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Figure 2.12: The USP7 binding motif of CHFR 177PSTS180 compared with that of 
p53 359PGGS362. A. An orientation of the CHFR peptide used to provide a standard view 
amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. CHFR has a PSTS motif, whereas p53 has PGGS, which 
is still a P/AXXS motif. Even though p53 contains two glycines instead of a serine and 
threonine, the most essential residues, S180 and S362 of CHFR and p53, respectively, 
are conserved and align perfectly. CHFR is displayed in yellow, and p53 in blue.  
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Figure 2.13: The USP7 binding motif of MCM-BP 177PSTS180 compared with that 
of EBNA1 444EGPS447. A. An orientation of the CHFR peptide used to provide a 
standard view amongst peptide comparisons. B. Rotated view to best portray a 
comparison of the residues involved in the motifs. The EGPS of EBNA1 in purple 
deviates completely from PSTS of CHFR in yellow except for the last serine. S180 in 
CHFR and S447 in EBNA1 align perfectly, as compared with the rest of the peptide 
which deviates at every residue.  
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2.3.3 USP7 is involved in the stability of endogenous CHFR 
A protein turnover assay for CHFR was performed in two cell lines of HEK293T cells – 
silenced USP7 (siUSP7) and negative control (siNC) - to compare the stability of CHFR 
in the absence and presence of USP7. USP7 was silenced using siUSP7 or left at 
endogenous levels with siNC. Cycloheximide treatment was administered to the cells 
after silencing USP7 and the level of CHFR was compared with cells in which USP7 was 
not silenced. Cells were harvested at the time points shown in figure 2.14 to analyze the 
amount of protein present in the two cell lines. The top two panels in figure 2.14A are 
blots showing a decreased level of USP7 in cells with siUSP7 as opposed to siNC. The 
curve in figure 2.14B displays quantified levels of USP7, with more than 50% of USP7 
knocked down in siUSP7 cells. From these figures it is also seen that USP7 stability is 
not affected over the 48 hours post-cycloheximide treatment in either experiment.  
The two blots in the center in figure 2.14A show the level of CHFR at each time point in 
the presence and absence of USP7. The expression levels were quantified and plotted as 
relative expression levels, in figure 2.14C. The amount of protein at the 0-time point was 
established as the reference level, at 100% for each cell line individually, and the stability 
of the protein was analyzed by comparing the levels at the consecutive time points with 
the reference level in that cell line. CHFR decreases steadily over the 48 hours in siUSP7 
cells, as opposed siNC cells where it remained close to a 100% until the 24-hour mark 
where it started to decrease. It is evident that the stability of endogenous CHFR was 
affected by the reduction in USP7 levels in the cell.  
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Figure 2.14: Stability of endogenous CHFR is affected by silencing USP7. A. USP7 
was silenced in HEK293T cells by transfection with 30nM siRNA (USP7 and negative 
control) for 72 hours. The cells were treated with cycloheximide (50 ug/ml) for 0, 2, 4, 8, 
24 and 48 hours post transfection. 100 ug of lysates for the respective cell lines were 
subjected to Western Blot analysis. Expression levels of endogenous CHFR over time 
were detected using anti-CHFR antibody, USP7 was detected using anti-USP7 antibody 
and anti-GAPDH was used to detect GAPDH as the loading control. B. Bands for USP7 
siUSP7 and siNC obtained from Western blotting were quantified using ImageJ (national 
Institute of Health). USP7 expression level post-cycloheximide treatment remains 
constant for each cell line; expression was knocked down in cells treated with siUSP7 
(orange) compared with siNC cells (blue). C. Bands obtained from western blotting were 
quantified using ImageJ software (National Institute of Health) and plotted as the relative 
expression of CHFR at each time point post-cycloheximide treatment. The expression 
level at the 0-hour point is set as the reference (100%), and the expression at each of the 
following time points is calculated as a percentage of the reference. CHFR degrades faster 
in USP7 knockdown cells (orange steeper curve) as compared with the negative control 
(blue curve).  
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2.3.4 UbE2E1 is not the ubiquitin conjugating enzyme associated with CHFR E3 ligase 
CHFR is an E3 ligase, with its respective E2 ubiquitin conjugating enzyme. UbE2E1 is 
an E2 and to determine if it’s the E2 for CHFR, a co-IP was performed from cells over-
expressing Flag-CHFR. The IP was performed with anti-Flag and anti-IgG (negative 
control), and western blotted for Flag (Flag-CHFR) and UbE2E1, as seen in figure 2.15. 
Both Flag-CHFR and UbE2E1 were seen in the lysate. However, UbE2E1 did not co-
immunoprecipitate with CHFR, since it is present only in the unbound sample, not in the 
eluate, indicating that it is not associated with CHFR. 
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Figure 2.15: UbE2E1 is not the ubiquitin conjugating enzyme associated with 
CHFR E3 ligase. Flag-CHFR was overexpressed in HEK293T cells. The cells were 
harvested after 48 hours and the lysate was immunoprecipitated with anti-Flag and anti-
IgG (negative control) beads. The unbound and wash fractions were collected and the 
proteins bound to the beads were eluted by boiling with 5XSDS dye. The co-
immunoprecipitated samples were resolved on a 10% SDS gel and subjected to Western 
Blotting. Flag-CHFR and UbE2E1 were detected with anti-Flag and anti-UbE2E1 
antibodies, respectively. UbE2E1 did not co-immunoprecipitate with CHFR in the eluate 
and was recovered only in the unbound fraction.  
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2.4 Discussion 
2.4.1 CHFR binds to the N-terminus of USP7 
In a previous study, CHFR was established as a substrate of USP7 (Oh et al. 2007) using 
a co-immunoprecipitation assay. The aim of this project was to determine the site of 
interaction, starting with determining the domain of USP7 that binds to CHFR. This was 
accomplished using a GST pull-down with GST-tagged USP7-NTD and Flag-CHFR. The 
result of this pull-down was compared with that of a control, whereby the GST protein 
was used instead of GST-USP7-NTD and the data is shown in figure 2.1. CHFR was 
successfully pulled-down with USP7-NTD. A portion of both CHFR and USP7 remained 
on the beads after elution, which could be due to insufficient elution. This data narrowed 
down the region that binds to CHFR to be the N-terminal domain of USP7, which has not 
been established prior to this project. This result was used for further experiments to 
determine the site of interaction on CHFR as well as the mode of interaction that allows 
the binding to occur.    
2.4.2 PSTS motif in CHFR involved in interaction with USP7-NTD 
Once a positive interaction was established, it was important to determine the site of 
interaction between the proteins. CHFR contains a PSTS-motif, which resembles the 
established P/AXXS substrate recognition motif found in substrates or interacting 
partners of USP7 (Sheng et al. 2006). This motif is recognized by a binding pocket in the 
N-terminus of USP7. Data from a peptide spot array and intrinsic tryptophan 
fluorescence assay helped confirm that this motif is responsible for binding to USP7.  
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Having determined the site of interaction in CHFR, the molecular mechanism was 
established using X-ray crystallography. Co-crystal trials were set up with USP7-NTD 
and peptides containing the PSTS motif in CHFR (174EPQPSTSTSD183), using 
microseeding with seeds from a previously crystallized complex of USP7-NTD:HdmX. 
HdmX, which is a negative regulator of p53, is also associated with USP7 using a 
P/AXXS motif. The complex of USP7-NTD:CHFRPSTS crystallized in the dark at 4⁰C, 
and the crystals were used to determine the molecular structures at a resolution of 1.6 Å.  
By aligning the CHFR peptide with USP7-NTD, it is seen that the peptide binds to the 
shallow groove on the surface of USP7, which is lined by the residues 164DWGF167. S180 
in CHFR makes the most contacts with D164 in USP7, with additional water-mediated 
hydrogen bonding between S178 in CHFR with USP7. By doing so, the peptide binds to 
the -7 strand in USP7-NTD and hugs the two anti-parallel beta-sheets created by the 
eight beta-strands.  
This mechanism of interaction is not unique to CHFR, but has been shown for almost all 
the proteins that bind to the N-terminal domain of USP7, such as p53, Hdm2, HdmX and 
EBNA1.  This, along with the fact that the conserved residues of the motifs of these 
proteins align well with those of CHFR, adds CHFR to a growing pool of proteins that 
make use of the substrate recognition motif and highlighting the importance of this mode 
of interaction for USP7.  
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2.4.3 USP7 is associated with the stability of CHFR 
CHFR is a mitotic checkpoint protein that is down regulated in a wide variety of cancers. 
It thus becomes essential to understand the mechanism revolving around its stability in 
the cell. USP7 was found to interact with CHFR, and being a deubiquitinating enzyme it 
was expected to be responsible for the stability of CHFR. It was hypothesized that the 
levels of CHFR would decay faster in the absence of USP7. Using a protein turnover 
assay in HEK293T cells, which express endogenous CHFR, USP7 was silenced or 
knocked down to less than 50% using siRNA, and the turnover of CHFR was observed. 
The half-life of CHFR was much shorter in cells with silenced USP7 than that with 
complete USP7 expression. Quantification of the bands obtained from western blots help 
to demonstrate this in figure 2.14C, where CHFR level in siUSP7 cells fall steadily, even 
within the first two hours after blocking the translational machinery, as opposed to those 
with siNC where the level remained close to a 100% for the first 24 hours.  
Theoretically it would be ideal to study endogenous CHFR in cancer cell lines, but given 
its lost and/or low expression in most tumor cells, it is difficult to detect changes, if any, 
in these cells. HEK293T cells, which are human embryonic kidney cells, were thus used 
for studying endogenous CHFR. Since this is not a cancer cell line, it also has the benefit 
of allowing to study the effect of USP7 depletion on CHFR in its normal unstressed 
environment.  
Oh et al. (2007) first detected the interaction between USP7 and CHFR. They also 
studied the effect of USP7 on the stability of CHFR, and found that USP7 was able to 
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stabilize CHFR. However, they used exogenous CHFR and exogenous USP7, and they 
used increasing amount of USP7 to detect increased overall levels of CHFR. This project, 
on the other hand, demonstrated that silencing USP7 de-stabilized CHFR over a certain 
time period, and more importantly, used endogenous proteins instead of ectopic thus 
eliminating the uncertainty of the behavior of an exogenously expressed protein.  
2.4.4 Perspective 
The interaction of USP7 with CHFR is still a novel interaction that researchers are 
beginning to explore. This project has determined the site of interaction of USP7 with 
CHFR, which was previously unknown. CHFR interacts with USP7 in the binding 
groove-dependent manner, and has been established as a substrate.  The molecular 
mechanism that governs this interaction has been seen previously with p53, Hdm2, 
HdmX and EBNA1, where a substrate recognition motif present in the substrates or 
interacting partners is recognized by a binding pocket on the surface of the N-terminal 
domain of USP7. 
The implications of USP7 and its involvement in the regulation of a checkpoint protein 
can be vast. This project has confirmed that the USP7:CHFR interaction involves the 
ability of USP7 to stabilize CHFR. CHFR is a checkpoint protein that is able to revert the 
cell cycle upon a signal of cellular stress and prevent the propagation of corrupted DNA. 
It makes sense that it’s seen to be either deleted or is expressed very poorly in most 
tumors. Exploiting the interaction between USP7 and CHFR could have potential to 
stabilize CHFR and prevent its degradation as a part of preventative therapy.  It could 
61 
 
also be used to stabilize the existing pool of CHFR in tumors that have low expression of 
CHFR, which may help in preventing the tumor from growing further. However, the 
interacting pair needs further examination, especially in terms of the network of proteins 
that must exist around CHFR’s checkpoint function. USP7 could play a role in the 
stability of proteins regulated by CHFR E3 ubiquitin ligase activity such as Aurora A and 
Plk-1. Aurora A and Plk-1 support mitosis, and as a part of its checkpoint function, upon 
stress CHFR ubiquitinates these proteins to prevent the cell from entering mitosis. It 
would thus be interesting to observe the effects of USP7 on Aurora A and Plk-1 stability 
and this may contribute to a network of regulation and feedback provided by USP7.  
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CHAPTER 3: INTERACTION STUDY BETWEEN USP7 
AND MCM-BP 
 
 
 
 
 
Some of the results presented in this chapter have been published in Molecular and 
Cellular Biology (MCB) under A Role for USP7 in DNA Replication. Jagannathan M, 
Nguyen T, Gallo D, Luthra N, Brown GW, Saridakis V, Frappier L. (Appendix A)  
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3.1 Introduction 
The transfer of genetic material from parent to daughter cell involves a complete and 
error-free replication of the genome. To accomplish this, eukaryotes have developed a 
highly complex, sensitive and regulated mechanism to carry out its DNA replication, 
starting with the recognition of origins of replication, loading the pre-RC (pre-replicative 
complex) and assembling the CMG helicase.  
3.1.1 Initiation of DNA replication 
During late M or early G1 phase, the origin recognition complex (ORC) locates the origin 
of replication and commences the assembly of a stable and inactive pre-RC (pre-
replicative complex) starting with CDC6, which recruits Cdt1 and together they recruit 
MCMs 2-7 to the DNA. This event licences the origin of replication and in late G1 or 
early S phase, the MCM 2-7 complex gets activated by cyclin-dependent kinases (CDKs) 
and a Dbf4-dependent kinase (DDK). The activated MCMs2-7 play a role in the 
recruitment and loading of CDC45 to the DNA, which is a DNA polymerase- loading 
factor (Bochman and Schwacha 2009). In addition, a complex of four subunits called the 
GINS complex, which is also a replication factor, is recruited to the replication site. 
Together, CDC 45, MCMs 2-7 and the GINS complex form a CMG helicase, responsible 
for unwinding the DNA double helix ahead of the replication fork and allowing for 
replication to occur in the S phase (Bryant and Aves 2011).  
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Figure 3.1: DNA replication initiation. In early G1 phase, the ORC complex initiates the licencing of 
the origin of replication by recruiting Cdt1, Cdc6 and the MCM 2-7 complex to the DNA to form a 
stable pre-replicative complex. At late G1 or early S phase, CDKs and DDK activate the MCM-
complex, leading to the recruitment of other replication factors to the DNA to form an active CMG 
helicase, which allows for replication to start in the S phase. (Bochman and Schwacha 2009) 
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The faithful propagation of genetic material should only happen once per cell cycle, and 
there are a large number of checks present in the cell that prevent re-initiation of 
replication. The pre-RC gets unloaded from replicated DNA to ensure it doesn’t start a 
second round. Once unloaded, there are multiple overlapping mechanisms that prevent 
the pre-RC from being re-assembled, where in one way or another the components of the 
complex are downregulated or kept away from each other (Nguyen et al. 2011).   
3.1.2 MCM-BP - unloading the MCM-complex  
The mechanism revolving around the displacement of the MCM helicase was unclear, 
until a protein sharing limited homology with MCM proteins was discovered in 2007 
called MCM-BP (minichromosome maintenance complex binding protein). It was 
observed to have the ability to replace MCM2 in the complex providing evidence for an 
alternate form of the complex (Sakwe et al. 2007). This alternate complex was found to 
be involved in the unloading of the pre-RC from replicated DNA.  
MCM-BP is imported into and accumulates in the nucleus in the late S phase, towards the 
end of replication. Coincidentally, this is when MCM2-7 was known to dissociate from 
the chromatin, and MCM-BP depletion was shown to result in delayed disassociation of 
the MCM proteins, as well as impaired mitotic entry (Nishiyama et al. 2011).  The 
clearing of the pre-RC from replicated DNA can have various implications, including the 
prevention of re-initiation of replication as well as successful chromosome segregation, 
thus providing evidence for MCM-BP to be a key player in maintaining genomic 
integrity (Nishiyama et al. 2011). 
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3.1.3 Objective and hypothesis 
A proteomic study identified an MCM-complex of 7-8 proteins to be a USP7 interacting 
partner (Sowa et al. 2009). The purpose of this interaction is yet to be understood. A 
sequence analysis revealed the presence of a P/AXXS motif on MCM-BP. Using 
structural studies, the purpose of this project is to determine if the USP7:MCM-BP 
interaction is via this recognition motif. The structure will enable us to visualize the 
location of interaction. By comparing this with previously established USP7-substrate 
protein interactions such as the USP7-p53 complex and combining with interaction 
assays can help us determine the purpose and mechanism of this interaction, thereby 
demonstrating a role of USP7 in the DNA replication process.  
It is expected that MCM-BP will interact with USP7-NTD using its substrate recognition 
motif, and that the mechanism will be similar to what has been observed in established 
USP7-NTD interactions.  
3.2 Materials and Methods 
3.2.1 Expression and purification of MCM-BP and USP7 
6xHis-MCM-BP (73 kDa) and 6xHis-USP7 (128 kDa) were expressed in Spodoptera 
frugiperda Sf9 cells using the baculovirus expression system, cultured at 27⁰C in Sf-900 
II SFM media (Life Technologies) supplemented with 5% FBS. The cells were harvested 
2-3 days post infection at 3000 x g for 10 mins and the pellets were washed three times 
with 1XPBS.  
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The proteins were purified using Ni2+ affinity chromatography. The cells were lysed by 
resuspending each gram of pellet in 10 ml Buffer A (20mM Hepes pH 7.5, 500mM NaCl, 
1mM -mercaptoethanol (-Me), 10% glycerol, 0.5% Nonidet P-40 (NP40), 10mM 
Imidazole, 1XProtease inhibitor cocktail) and incubating on ice for 45 minutes, followed 
by sonication for 3 min, 30% Amp, 15 sec ON 10 sec OFF. The suspension was 
centrifuged at 27,000 x g for 30 mins in a Beckman-Coulter Avanti JE centrifuge with a 
JA 25.50 rotor. The lysate was applied to Buffer A equilibrated Ni2+-agarose beads and 
allowed to bind for 60 minutes. Unbound proteins were collected and the resin was 
washed three times with 150 ml of Buffer B (20mM Hepes pH 7.5, 500mM NaCl, 1mM 
-Me, 10% glycerol, 10mM Imidazole, 1XProtease inhibitor cocktail). The protein bound 
to the resin was eluted using Buffer C (20mM Hepes pH 7.5, 500mM NaCl, 1mM -Me, 
10% glycerol, 500mM Imidazole, 1XProtease inhibitor cocktail) and the eluate was 
subjected to a size exclusion Hi Load 16/60 Superdex 200 prep grade column (GE 
Healthcare) on an AKTA Purifier (GE Healthcare) using Buffer D (20mM Hepes pH 7.5, 
300mM NaCl, 0.5mM tris(2-chloroethyl)phosphate TCEP).  
3.2.2 Testing molar ratio of interaction between MCM-BP and USP7 
The interaction between MCM-BP and USP7 was tested with eight different molar ratios 
of MCM-BP:USP7 – 1:0, 0:1, 1:1, 1:1.5, 1:2, 1:5, 2:1, and 5:1. The NaCl concentration 
of both proteins was diluted to 50mM from 300mM using 20mM Hepes pH 7.5 to avoid 
salt interference during interaction. The proteins were combined in their respective ratios; 
20mM Hepes pH 7.5 was used to substitute for each of the absent protein in the controls 
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(1:0 and 0:1). The reaction mixture was incubated at room temperature for 60 minutes, 
following which the samples were concentrated using a VivaSpin6 50 kDa MWCO (GE 
Healthcare) concentrator to a final volume of 250 µl and subjected to size exclusion 
chromatography using a Superdex 200 10/300 GL column (GE Healthcare) on an AKTA 
Purifier (GE Healthcare). Two major peaks were obtained for each run at fractions D10 
and E8, and samples taken from fractions C9, 11, 12, D2, 4, 6, 8, 10, 12, E2, 4, 6, 8, 10, 
12, F2, 4, 6 and G6 were resolved on a 10% SDS gel (20 µl  sample with 5 µl  5XSDS 
dye). A GeneDireX PINK Plus Prestained Protein Ladder was used as a MW reference 
and the gel was run at 195V for 75 minutes.  
2.2.5 Molecular basis of interaction between USP7-NTD and MCM-BP 
Expression and purification of USP7-NTD 
E. coli DE3 cells containing a plasmid encoding for 6xHis-tagged USP7-NTD were 
cultured in TB (Terrific Broth, Bioshop) with 100 ng/ml ampicillin and expression was 
induced overnight using 0.4mM IPTG at 16⁰C. The cells were harvested at 7,446 x g for 
30 minutes at 4⁰C. The resulting pellet was lysed with 4 ml of Lysis Buffer per gm of 
pellet (100mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 10mM Imidazole, 0.5mM 
TCEP, 1XProtease inhibitor cocktail). The cells were sonicated at 30% amplitude, 15 sec 
ON 10 sec OFF for a total ON time of 6 minutes, with a pause after 3 minutes. The lysed 
cells were centrifuged at 41,287 x g for 30 minutes at 4 ⁰C. A sample was taken from the 
supernatant for SDS PAGE analysis and the remaining lysate was incubated with Ni2+ 
agarose beads equilibrated with the Lysis Buffer, with gentle rocking at 4⁰C for 2 hours. 
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The proteins left unbound after binding were collected and the resin was washed with 100 
ml of Wash Buffer (100mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 25mM 
Imidazole, 0.5mM TCEP). The wash was collected and the isolated protein was eluted 
with Elution Buffer (100mM Hepes pH 7.5, 500mM NaCl, 10% glycerol, 250mM 
Imidazole, 0.5mM TCEP).  
Samples obtained from lysate, unbound proteins, wash and elute (16 µl sample + 4 µl 
5XSDS dye) were resolved on a 10% SDS gel at 195V for 65 minutes and a PageRuler 
Prestained Protein Ladder was used as a MW reference. 
The purified 6xHis-USP7-NTD contains a thrombin cleavage site between the His-tag 
and the protein. To cleave the 6xHis-tag, the protein was incubated with 0.5 units 
thrombin (Sigma T6884) per mg protein and 2.5mM CaCl2 for 72 hours at 4⁰C. Samples 
of the protein were taken before and after cleavage (His-uncleaved and His-cleaved, 
respectively) and resolved on a 15% SDS gel run at 220V for 35 minutes. The marker 
used was PageRuler Prestained Protein Ladder.   
The His-cleaved USP7-NTD was then subjected to size exclusion chromatography using 
a HiLoad 16/60 Superdex 200 prep grade column (GE Healthcare) on an AKTA purifier 
(GE Healthcare) to further remove impurities from the protein and to exchange the 
protein into 20mM Hepes pH 7.5, 500mM NaCl. The cleaved dialyzed protein was used 
for protein crystallization trials.  
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Co-crystallization trials of USP7-NTD with MCM-BPPSTS peptide 
5-fold molar excess of MCM-BP peptide 152RVSPSTSYTP161 with N-terminal 
acetylation and C-terminal amidation (synthesized by CanPeptide Inc.) was incubated 
with 100 mg/ml of USP7-NTD, overnight at 4⁰C. Seeds from crystals of USP7:HdmX 
complex were used to set up co-crystal trials using microseeding in a crystallization 
condition of 0.1 M Tris pH 8.5, 30% PEG 4000, and 0.2 M Lithium Sulfate.  
X-ray data collection and molecular structure determination 
X-ray diffraction data was collected from a frozen USP7:MCM-BP crystal at 100K on a 
Rigaku MicroMax007 rotating anode diffractometer with a 944+ CCD (charge-coupled-
device) detector. HKL2000 (Otwinowski and Minor 1997) was used to integrate and 
scale the diffraction data and molecular replacement was used to determine the structure. 
USP7 54-205 (PDB identifier [ID] 1YY6) without any peptide was used as the search 
model in CNS program (version 1.3) (Brunger 2007). The electron density was visualized 
and the model was rebuilt using the molecular graphics program O (Jones and Kjeldgaard 
1997). CNS 1.3 was used for refinement and 2Fo-Fc and Fo-Fc maps were inspected for 
further refinement and model rebuilding in O. Water molecules were picked using CNS 
1.3 and verified in O. The figures were created using the software program PyMOL 
(version 1.3).  
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3.3 Results 
3.3.1 Expression and purification of MCM-BP and USP7 
MCM-BP and USP7 were purified from SF9 cells using Ni2+ affinity chromatography, 
followed by a second round of purification using size exclusion chromatography. Figures 
3.2 and 3.3 represent samples from both rounds of purifications, for MCM-BP and USP7, 
respectively. The eluate contains the proteins after Ni2+ affinity purifications, whereas 
the lanes following that show samples taken from fractions obtained after size exclusion, 
with the fractions highlighted in green pooled and collected for use in further 
experiments. MCM-BP is detected at 73 kDa and USP7 at 128 kDa. MCM-BP was 
concentrated to 0.67 mg/ml while USP7 was concentrated to 1.71 mg/ml.  
The yield from the purifications was not high, as is seen from the faint bands observed, 
but enough was obtained to allow for determining the molar ratio of interaction between 
the two proteins.  
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Figure 3.2: Purification of MCM-BP using Ni2+ affinity chromatography. 6xHis 
tagged MCM-BP (642 amino acid residues, 73 kDa protein) was overexpressed in SF9 
cells using the baculovirus expression system and purified using Ni2+ affinity 
chromatography followed by size exclusion chromatography. Samples from lysate, 
unbound proteins, wash and elute from the first round of replication, as well as from 
fractions obtained from the second round were collected and separated on a 15% gel 
at 195V for 65 minutes A band can be seen in Elute at ~73 kDa, representing 6xHis-
MCM-BP. Bands at the same position can be seen in the fractions highlighted in green, 
which were pooled and concentrated to 0.67 mg/ml, to be used in determining the 
molar ratio of interaction between USP7 and MCM-BP. The ladder used was 
PageRuler Plus Prestained Protein Ladder.   
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Figure 3.3: Purification of USP7 using Ni2+ affinity chromatography. 6xHis tagged 
USP7 (1102 amino acid residues, ~130 kDa protein) was overexpressed in SF9 cells using 
the baculovirus expression system and purified using Ni2+ affinity chromatography. 
Samples from lysate, unbound proteins, wash and elute were collected and separated on 
a 15% gel at 195V for 65 minutes A band can be seen in Elute at ~130 kDa, representing 
6xHis-USP7. The eluate was subjected to size exclusion chromatography, fractions from 
which were also resolved using SDS-PAGE. The eluate was run again, along with samples 
from size exclusion, to provide a size comparison for the second gel. The fractions 
highlighted in green were pooled, concentrated to 1.71 mg/ml and used in determining 
the molar ratio of interaction between USP7 and MCM-BP. The ladder used was 
PageRuler Plus Prestained Protein Ladder.   
USP7  
128 kDa 
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3.3.2 Equimolar and 1:1.5 ratio of MCM-BP: USP7 facilitates interaction 
MCM-BP and USP7 were expressed in Sf9 cells using the baculovirus expression system 
and purified using Ni2+ affinity chromatography. They were then mixed in molar ratios of 
MCM-BP: USP7 - 1:0, 0:1, 1:1, 1:1.5, 1:2, 1:5, 2:1, and 5:1, incubated to allow for 
interaction and subjected to size exclusion chromatography to separate complexed 
proteins from fractions with individual unbound proteins. Figure 3.4 displays the size 
exclusion chromatograms for the various molar ratios tested, where the major peaks 
observed were at fractions D10 and E8, for USP7 and MCM-BP, respectively (figure 
3.4A and B). As the molar ratios are changed, the intensity (height) of the peaks changes 
respectively.  
Fractions from the peaks as well as before and after each peak were resolved using SDS-
PAGE to visualize the contents of each peak, as seen in figure 3.5, with USP7 at 128 kDa 
and MCM-BP at 73 kDa. An interaction between the two proteins is positive if they are 
present in the same fractions. As controls to determine the location of the two proteins 
individually, MCM-BP is seen from fractions E6-E10, whereas USP7 is seen mainly 
from D6-E2, as displayed in the top two panels (1:0 and 0:1). When either protein is in 
twice the excess, or more, of the other, the two proteins are not visible in the same 
fractions and thus interaction was not facilitated at these ratios (bottom four panels). 
However when the two proteins are in an equimolar ratio or a small excess of MCM-BP 
(1:1 or 1:1.5, respectively), they are present in the same fractions, suggesting a successful 
interaction between the two proteins at these ratios.  
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Figure 3.4: Size exclusion chromatographs testing interaction molar ratio between 
MCM-BP and USP7. Full length USP7 and MCM-BP proteins were purified from SF9 
cells and incubated together in various molar ratios at room temperature for 1 hour to 
determine optimal ratio for interaction. This was subjected to size exclusion 
chromatography to separate bound and unbound fractions. A-H represent 
chromatographs for molar ratios of (MCM-BP:USP7) 1:0, 0:1, 1:1, 1:1.5, 1:2, 1:5, 2:1 
and 5:1, respectively. Major peaks were observed at D10 and E8. Fractions from, before, 
and after each peak were separated using SDS-PAGE. 
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Figure 3.5: Equimolar and 1:1.5 ratio of MCM-BP:USP7 facilitates interaction. USP7 and 
MCM-BP were purified and incubated together in various molar ratios at room temperature for 1 
hour to determine optimal ratio for interaction. This was subjected to size exclusion 
chromatography and fractions from, before, and after each peak (D10 and E8) were separated 
using SDS-PAGE on a 10% gel. The top two panels contain MCM-BP and USP7 controls, where 
the proteins can be seen at 73 kDa and 128 kDa respectively. When the molar ratio is increased 
more than 1.5 fold, MCM-BP and USP7 do not elute in the same fraction showing that greater 
than 1:1.5 ratio does not facilitate interaction. 
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3.3.3 Molecular basis of interaction of USP7 with MCM-BPPSTS involves its 
164DWGF167 binding pocket 
To determine the molecular basis of interaction, co-crystal structure of USP7-NTD with 
peptide from MCM-BP was determined using X-ray crystallography. USP7-NTD was 
purified using Ni2+ affinity chromatography, as shown in Chapter 2.  
Co-crystallization trials and molecular structure determination  
5-fold excess of the MCM-BP peptide was successfully co-crystallized with His-cleaved 
USP7-NTD in 0.1M Tris pH 8.5, 30% PEG 4000 and 0.2M Lithium Sulfate. 
Microseeding was used to enhance the crystallization process by using crystals from the 
USP7:HdmX complex as seeds. Figure 3.6 displays long rod shaped crystals obtained 
from the crystallization trials, similar to what was observed in crystals from the 
USP7:CHFR complex. Data collected from X-ray diffraction using one crystal was used 
to determine the three-dimensional structure of the complex. Figure 3.7A is one of the 
multiple diffraction images collected, with the red rings displaying the resolution shells. 
Each spot on the image is a reflection of the diffracted X-rays detected by the CCD 
detector. Figure 3.7B is an intensified version of the original image to show the 
reflections at higher resolution shells, as shown in the magnified image around the 2.08Å 
shell.  
Molecular replacement was used to solve the structure at a resolution of 1.7 Å. Table 3.1 
lists the X-ray data collection and refinement parameters for this structure. The unit cell 
was found to be P41 with a = b = 70.0 Å and c = 45.7 Å unit cell parameters. The data 
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collection was 76.7% complete at the 1.7 Å resolution shell. After refinement, the Rwork 
and Rfree were shown to be 20.7% and 23.3%, respectively, well within acceptable limits. 
Additionally, 89% of residues were found to be in their most favored regions in the 
Ramachandran plot, which further signals the validity of the determined structure. 
MCM-BP binds to the -7 strand in a groove on the surface of USP7 
 Figure 3.8 displays the complex structure, with USP7-NTD in violet depicted as a ribbon 
diagram (figure 3.8A), surface diagram (figure 3.8B) and electrostatic surface diagram 
(figure 3.8C), and the MCM-BP peptide represented as a stick diagram in green. USP7-
NTD was modeled from residues 63-205, due to residues 54-63 being disordered. The 
structure consists of an anti-parallel beta-sandwich of eight -strands that resembles a 
TRAF domain. The MCM-BP peptide is seen to interact with USP7-NTD by interacting 
with its 7 strand while hugging the two beta-sheets along its length. The view of the 
structure as shown in figure 3.8 will, for comparison purposes, be considered as the 
frontal view, which is the view that best displays the structure as a complex. 
When the structure was rotated 90⁰ from its frontal view, a shallow groove on the surface 
of USP7-NTD was visible, and the MCM-BP peptide was seen to fit well in this groove 
through its interaction with the -7 strand which lies at the base of the groove, as 
depicted in figure 3.9.  
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Figure 3.6: Protein crystals of USP7-NTD complex with MCM-BP peptide. 100 
mg/ml USP7-NTD was incubated with approximately 5-fold excess of MCM-BP
PSTS
 
peptide. Co-crystal trials were set up using micro-seeding with USP7-NTD:HdmX 
as seeds in 30% PEG 4000, 0.1 M Tris pH 8.5 and 0.2 M Lithium Sulfate. Crystals 
were obtained from complex of USP7-NTD with MCM-BP peptide 
152
RVSPSTSYTP
161
 in the dark at 4⁰C and used to collect X-ray data and solve the 
three-dimensional structure of the USP7-NTD:MCM-BP
PSTS
 complex.  
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  Figure 3.7: X-ray diffraction pattern from a USP7:MCM-BP complex crystal. X-ray 
data from a Rigaku MicroMax007 rotating anode diffractometer with a 944+ CCD 
(charge-coupled-device) detector was collected at 100K from a frozen protein crystal. 
When the X-rays pass through the crystal, a constructive interference of the X-rays 
produce reflections on the detector, which as seen as spot on the images. A. Image of the 
diffraction pattern displaying reflections at the low-medium resolution shells. B. Image 
showing the reflections at the higher resolution shells, with a magnified section around 
2.08Å.  
B 
A 
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Table 3.1. X-Ray data collection and refinement parameters for USP7:MCM-BP complex 
Numbers in brackets refer to the highest resolution shell, 1.73 to 1.70 Å for the MCM-
BP
PSTS
 data. 
a
R
sym
 = S |I-<I>| /SI where I is the observed intensity and <I> is the average 
intensity from multiple observations of symmetry-related reflections.  
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-7 
C 
N 
B 
C 
Figure 3.8: Crystal structure of USP7-NTD bound to MCM-BP 
152
RVSPSTSYTP
161
. 
A. Cartoon representation of the crystal structure of MCM-BP peptide in green bound to 
the USP7-NTD in violet ribbon form at its -7 strand. B. Surface diagram and C. 
Electrostatic surface representation of the crystal structure. The complex structure was 
solved at a resolution of 1.7 Å.  
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90⁰ 
90⁰ 
A 
B 
Figure 3.9: MCM-BP binds to a shallow groove on the surface of USP7. Upon rotating 
the structure on the x-axis at a 90⁰ angle, the MCM-BP peptide is observed to be sitting 
in a shallow groove on the surface of USP7. At the base of the groove is the -7 strand of 
the anti-parallel beta-sheets of the N-terminal domain of USP7. A. Cartoon and B. Surface 
representations of the frontal view as well as the rotated, to allow for visualization of the 
binding groove. The peptide is represented in green stick form.  
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The interaction site – S158 of MCM-BP makes most contacts with D164 of USP7 
To take a closer look at the site of interaction, the MCM-BP peptide is aligned with the 
interacting residues from USP7, in figure 3.10B. It is clear that there are two interactions 
that bind the two proteins. By rotating this figure, these interactions are better displayed 
in figures 3.10C and D. The most essential residues are seen to be S158 in MCM-BP 
which makes hydrogen bonds with D164 of USP7 (figure 3.10C). The carboxyl groups of 
the aspartate side chain (D164) in USP7 form hydrogen bonds with the amide of the 
serine as well as the hydroxyl of the serine side chain (S158) in MCM-BP. Additional 
binding is achieved through water-mediated hydrogen bonding of S156 with USP7 
(figure 3.10D). These interactions allow the peptide to sit in the groove on the surface of 
USP7 lined by the residues 164DWGF167. Figure 3.10A shows the peptide modelled into 
its electron density map. At the 1.7Å resolution, the density for the side chains is clear 
and the side chains fit well.  
To provide orientation clarity, the orientation of the peptide observed in figure 3.10A and 
B is considered as the standard orientation, and will be used with every depiction of the 
peptide, along with a rotated view to provide the optimal visualization of the site of 
interest.  
MCM-BP peptide forms a ninth beta-strand anti-parallel to -7 of USP7 
Figure 3.11 compares the complex structure with the peptide in stick form with that as a 
strand. When the frontal view of the structure is rotated in three dimensions, the peptide 
in stick form is seen to line up against the -7 strand of USP7. Interestingly, with a part 
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of the peptide transformed to a ribbon diagram, it is observed to form an anti-parallel 
strand to the -7 strand.  
Comparing the substrate recognition motif of MCM-BP with USP7 interacting peptides 
Figures 3.12-3.15 compare the MCM-BP peptide with other USP7-NTD interacting 
peptides from CHFR, MDM2, p53 and EBNA1, respectively, by aligning these peptides 
with MCM-BP. The USP7 substrate recognition motif in MCM-BP is PSTS, which is 
compared with the motifs in CHFR, MDM2, p53 and EBNA1. Like MCM-BP, CHFR 
uses PSTS to interact with USP7, so their motifs align perfectly. The motifs in MDM2 
and MCM-BP differ by one residue, with MDM2 using PSSS instead of PSTS. p53 only 
shares the proline and last serine with MCM-BP, but still maintains the P/AXXS 
conservation. EBNA1, however, does not conform to the P/AXXS, using EGPS. It does 
not align well with MCM-BP, yet the last serine in the motif which interacts with D164 
of USP7 is conserved and aligns perfectly.  
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Ser 158 
Asp 164 
Ser 156 
Pro 155 
Phe 167 
H2O 
A 
C D 
Figure 3.10: 155PSTS158 of MCM-BP interacts with 164DWGF167 in the binding groove 
of USP7. A. The electron density map (2fo-fc) of the MCM-BP peptide. B. The peptide 
in green aligned with the interacting residues of USP7, in violet. C. MCM-BP S158 
(Ser158) makes contacts with D164 (Asp164) of USP7 using hydrogen bonds. D. In 
addition, S156 (Ser156) aids in the interaction by forming water-mediated hydrogen 
bonds with USP7. C. and D. are rotated views of A, to better display the S158-D164 and 
the water-mediated interactions, respectively.  
Ser 158 
Asp 164 
Ser 156 
Pro 155 
Phe 
167 
Trp 165 Thr 157 
Gly 
166 
B 
Pro 155 
Ser 158 
Ser 156 
Thr 157 
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Figure 3.11: The MCM-BP peptide forms an antiparallel strand. A. When the 
USP7:MCM-BP structure is rotated from its frontal view in three dimensions, the peptide, 
in stick form, is seen to line up against the upper beta-sheet of USP7. Viewing the peptide 
as a strand instead of stick-model, as seen in B, enables visualization of it as forming an 
anti-parallel strand to the -7 strand of USP7.  
A B 
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Pro 155 Pro 177 
Ser 156 
Thr 157 Ser 158 
Ser 178 
Thr 179 
Ser 180 
C 
N 
Pro 155 
Ser 156 
Thr 157 
Ser 158 
Pro 177 
Ser 178 
Thr 179 
Ser 
180 
C 
N 
A B 
Figure 3.12: The USP7 binding motif of MCM-BP 155PSTS158 compared with that of 
CHFR 177PSTS180. A. An orientation of the MCM-BP peptide used to provide a standard 
view amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. MCM-BP and CHFR both have a PSTS motif, hence the 
peptides line up perfectly at their motifs. MCM-BP in green and CHFR in yellow.  
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Pro 155 
Ser 156 
Thr 157 
Ser 158 
Pro 147 
Ser 148 
Ser 149 
Ser 150 
C 
N 
Pro 155 
Ser 156 
Thr 157 
Ser 158 
Pro 147 
Ser 148 
Ser 149 
Ser 150 
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N 
A B 
Figure 3.13: The USP7 binding motif of MCM-BP 155PSTS158 compared with that of 
MDM2 147PSSS150. A. An orientation of the MCM-BP peptide used to provide a standard 
view amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. MCM-BP has a PSTS motif, whereas MDM2 uses PSSS. 
The difference in T157 of MCM-BP and S149 of MDM2 can be seen, with MCM-BP in 
green and MDM2 in red. The S158 and S150 of MCM-BP and MDM2, respectively, align 
well.  
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Pro 155 
Ser 156 
Thr 157 
Ser 158 
Pro 359 
Gly 360 
Gly 361 
Ser 362 
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N 
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Pro 155 
Ser 156 
Thr 157 
Ser 158 
Pro 359 
Gly 360 
Gly 361 
Ser 362 
N 
C 
B 
Figure 3.14: The USP7 binding motif of MCM-BP 155PSTS158 compared with that of 
p53 359PGGS362. A. An orientation of the MCM-BP peptide used to provide a standard 
view amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. MCM-BP has a PSTS motif, whereas p53 has PGGS, 
which is still a P/AXXS motif. Even though p53 contains two glycines instead of a serine 
and threonine, the most essential residues, S158 and S362 of MCM-BP and p53, 
respectively, are conserved and align perfectly. MCM-BP is seen in green, and p53 in blue.  
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Pro 155 
Ser 156 
Thr 157 
Ser 158 
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444 
Gly 445 
Pro 446 
Ser 447 
C 
N 
Glu 444 
Gly 445 
Pro 446 
Ser 447 
Pro 155 Ser 156 
Thr 157 
Ser 158 
N 
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A B 
Figure 3.15: The USP7 binding motif of MCM-BP 155PSTS158 compared with that of 
EBNA1 444EGPS447. A. An orientation of the MCM-BP peptide used to provide a standard 
view amongst peptide comparisons. B. Rotated view to best portray a comparison of the 
residues involved in the motifs. MCM-BP has a PSTS motif, whereas EBNA1 contains 
EGPS, which is deviates from the MCM-BP motif except for the last conserved serines. 
S158 in MCM-BP and S447 in EBNA1 in green and purple, respectively, align perfectly, 
as compared with the rest of the peptide which deviates at every residue.  
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3.4 Discussion 
After a proteomics study revealed that MCM-BP was a possible interacting partner of 
USP7, this project was undertaken to confirm the interaction and to determine the site 
and molecular basis of interaction.  
3.4.1 MCM-BP binds to USP7 in a 1:1 molar ratio. 
The molar ratio of interaction between USP7 and MCM-BP was tested to determine 
optimal interaction conditions. It was expected that, if interacting, the optimal ratio would 
be 1:1, which is validated by the data that shows that the proteins bind when present in a 
1:1 as well as 1:1.5 ratio of MCM-BP:USP7. A successful binding is suggested when the 
two proteins being tested co-elute in the same peak or fractions from a size exclusion 
column. This is visualized by a shift in the peaks in a chromatogram when compared to 
the peaks of the individual proteins (figure 3.4) as well as on a SDS-PAGE gel with 
samples from fractions of and around the peaks (figure 3.5). As seen in figure 3.5, at 
ratios other than 1:1 and 1:1.5, no binding was observed, as the proteins were not present 
in the same fractions. Ideally, the proteins would bind only in a 1:1 ratio, however 
binding at 1.1.5 ratio might suggest that the molar ratio requirement may not be as rigid 
as expected. Jagannathan et al (2014) conducted a similar experiment where they used 
equimolar concentrations of USP7 and MCM-BP and observed positive binding. 
However, their experiment differs from this project since they compared the interaction 
of MCM-BP with different regions of USP7, whereas we compared different ratios of 
interaction.  
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3.4.2 PSTS motif in MCM-BP involved in interaction with USP7-NTD 
Once a positive interaction was established, it was important to determine the site of 
interaction between the proteins. MCM-BP contains a PSTS-motif, which resembles the 
established P/AXXS substrate recognition motif found in substrates or interacting 
partners of USP7 (Sheng et al. 2006). This motif is recognized by a binding pocket in the 
N-terminus of USP7. Data from a peptide spot array and intrinsic tryptophan 
fluorescence assay helped confirm that this motif is responsible for binding to USP7. The 
serines in the motif were seen to be essential for binding; mutation of either of the serines 
to alanine abolished binding and the dissociation constant for the interaction resulted in 
being significantly higher than the wild type. 
Having determined the site of interaction in MCM-BP, the molecular mechanism was 
established using X-ray crystallography. Co-crystal trials were set up with USP7-NTD 
and peptide containing the PSTS motif in MCM-BP (152RVSPSTSYTP161), using 
microseeding with seeds from a previously crystallized complex of USP7-NTD:HdmX. 
The USP7-NTD:MCM-BPPSTS complex crystallized in the dark at 4⁰C, and was used to 
determine the molecular structure at a resolution of 1.7Å.  
Similar to the mode of binding observed in CHFR, by aligning the MCM-BP peptide 
with USP7-NTD, it is seen that peptide binds to the same shallow groove on the surface 
of USP7, lined by the residues 164DWGF167. The last serine in the PSTS motif, S158, is 
responsible for making contacts with D164 in USP7, with additional hydrogen bonding 
between the peptide and USP7 facilitated by a water molecule. USP7-NTD makes two 
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anti-parallel beta-sheets using eight strands, and the peptide is observed to bind to the -7 
strand, while hugging the two beta-sheets. As seen from interaction study with CHFR, 
this mechanism of interaction is not unique to MCM-BP, but has been shown for almost 
all the proteins that bind to the N-terminal domain of USP7, such as p53, Hdm2, HdmX 
and EBNA1.  
Upon comparison of MCM-BP with these proteins, despite the neighboring residues of 
the motifs being different, the motifs themselves align well in MCM-BP with those in 
CHFR, MDM2 and p53. In EBNA1, only the last serine is conserved, yet the backbone 
aligns well with the serine lining up perfectly. This highlights the conserved mechanism 
used by these proteins to interact with USP7, despite their varied functions.  
3.4.3 Perspective 
The interaction of USP7 with MCM-BP is still a novel interaction that researchers are 
beginning to explore. MCM-BP is essential in the unloading of the pre-RC from DNA 
towards the end of replication, helping to prevent the cell from duplicating the DNA 
more than once. Determining the site and molecular mechanism of interaction between 
USP7 and MCM-BP has played a role in portraying the importance of USP7 in DNA 
replication. Jagannathan et al. (2014) have recently shown that by binding to USP7 on the 
chromatin, MCM-BP is capable of mediating an interaction between USP7 and the MCM 
proteins leading to their dissociation from the DNA by a still unknown mechanism.  
Their study might also indicate a non-catalytic role between USP7 and MCM-BP. Most 
proteins, such as p53, Hdm2 and HdmX that bind to the binding pocket in the N-terminus 
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of USP7 are involved as substrates in a catalytic role with USP7. This project has 
determined MCM-BP to bind USP7 in a similar fashion to these proteins, but may only 
be an interacting partner, not a substrate for deubiquitination.  
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CHAPTER 4: SUMMARY AND 
 FUTURE PROSPECTS  
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4.1 Summary and conclusion 
The aim of this project was to study the interactions of the N-terminal domain of USP7 
with MCM-BP and CHFR by determining the molecular mechanism of these interactions 
in vitro and studying the effect of USP7 depletion on CHFR in vivo. Using X-ray 
crystallography, it was found that a PSTS-motif in both MCM-BP and CHFR bind to a 
shallow groove on the surface of USP7-NTD lined by residues 164DWGF167, with a major 
interaction established between S158 of MCM-BP and S180 of CHFR with D164 of 
USP7. Additional water-mediated hydrogen bonds were also formed between USP7 and 
S156 of MCM-BP and S178 of CHFR. This mechanism underlying this interaction was 
observed to be similar to those established with the interactions of USP7 with p53, 
EBNA1, MDM2 and MDMX. The in vivo study between USP7 and CHFR confirmed 
that endogenous CHFR gets degraded faster in the absence of endogenous USP7, 
concluding that the deubiquitinating activity of USP7 is involved in stabilizing the levels 
of CHFR. Although previous studies have established the interaction of USP7 with 
MCM-BP and CHFR, this study was the first to map these interactions to the N-terminus 
of USP7.  
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4.2 Future prospects 
4.2.1 Expanding the CHFR-USP7 network 
USP7 is a key player of the p53-MDM2 pathway, where it is responsible for the 
deubiquitination of both p53 as well as MDM2, the E3 ligase responsible for 
ubiquitinating p53. Being the DUB for CHFR, which is an E3 ligase, it is then possible 
that USP7 also plays a role in the regulation of the substrates of CHFR, such as Aurora A 
and Plk-1. Aurora A contains three potential USP7 substrate recognition motifs, PSNS, 
APSS and ANSS, while Plk-1 contains only APSS. Using a combination of mutational 
analysis, peptide spot array and intrinsic tryptophan assay, one of these motifs can be 
validated and used for future research with the interaction of the two proteins with USP7. 
As mentioned, this would pave the way towards expanding the CHFR-USP7 network to 
understand the pathways that would tightly govern the regulation of such an essential 
checkpoint protein.  
To function in its E3 ligase capacity, CHFR requires E2 ubiquitin conjugating enzymes to 
ubiquitinate a substrate. Since CHFR shares its RING domain with RNF8, it would be 
interesting to study its interactions with the E2s associated with RNF8. UbE2E1 was one 
such E2 that interacts with RNF8 but was found not to be associated with CHFR. Each 
E3 ligase can pair with a variety of E2 proteins, and there is a constant effort to find 
novel E2-E3 pairs. As such, the search for E2s to pair with CHFR can continue, with 
those interacting with RNF8 used as a starting point.  
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4.2.2 Examine the mechanism involved in USP7-mediated MCM unloading 
The interaction between MCM-BP and USP7 has now been characterized and it has been 
shown by Jagannathan and colleagues (Jagannathan et al. 2014) to be essential for the 
dissociation of the MCM complex from chromatin. This interaction may not be a 
catalytic interaction, and both MCM-BP and USP7 are required for successful 
dissociation. The mechanism of this process is still unclear. USP7 could potentially be 
involved in deubiquitination of one of the MCM complex proteins. In fact, MCM3 
contains residues PSSS, identical to the motif used by MDM2 to bind USP7. MCM5 also 
includes residues that conform to the general P/AXXS motif – ASPS.  
The affinity of these proteins for USP7 can be determined using interaction assays, while 
the viability of the motifs can be checked using a peptide array and intrinsic tryptophan 
fluorescence assay. If there is a positive interaction of these proteins with USP7, a 
combination of experiments can be used to analyze if the interaction is catalytic and 
further, if this affects the stability of the proteins. Deubiquitination of these proteins as a 
part of the unloading process (proteasome independent) would mean conformational 
changes in the MCM protein, which would provide an insight into the mechanism 
responsible for the dissociation of the complex.  
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